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Abbreviations 
AC  Amadori compound 
ACN  acetonitrile 
AGE  advanced glycation endproduct 
CE  capillary electrophoresis 
CHCA  α-cyano-4-hydroxycinnamic acid 
DHB  2,5-dihydroxybenzoic acid 
DTT  dithiotreitol 
ESI  electrospray ionization 
FAB  fast atom bombardment 
FIA  flow injection analysis 
FL  fructosyl lysine 
FL-18  fructosyl lysine after loss of water 
HbA1c hemoglobin A1c 
HPLC  high performance liquid chromatography 
HSA  human serum albumin 
ISD  in-source decay 
LC  liquid chromatography 
LC-MS liquid chromatography coupled with mass spectrometry 
LDI  laser desorption ionization 
MALDI matrix assisted laser desorption/ionization 
MALDI-TOF/MS matrix assisted laser desorption/ionization time of flight mass 
spectrometry 
MS  mass spectrometry 
ODS  octadecil silane 
PBS  phosphate buffers saline 
PMF  peptide mass fingerprint 
PSD  post source decay 
PTM  post translational modification 
RNAse ribonuclease A 
RP  reversed phase  
RSD  relative standard deviation 
SA  sinapic acid 
SPE  solid phase extraction 
TFA  trifluoroacetic acid 
THAP  2,4,6-trihydroxyacetophenone 
THF  tetrahydrofurane 
TOF  time of flight 
TRIS  tris(hydroxymethyl)aminomethane 
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1. Introduction 
1.1 Identification of peptides and proteins by MALDI-TOF mass spectrometry 
technique 
Matrix assisted laser desorption/ionization (MALDI) was first described by Karas and 
Hillenkamp in 1988 [1]. MALDI is an improvement of the laser desorption ionization (LDI). 
In LDI the ionization is performed by irradiating with an ultraviolet laser. The disadvantage of 
LDI is that it has low sensitivity, the ionization causes ion fragmentation, and the signal is 
very dependent on the ultraviolet-adsorbing characteristics of the analyte [2]. As a result, this 
method is unsuitable for larger molecules like proteins, DNA, RNA etc.. To eliminate these 
problems, the analyte is mixed with a compound, the matrix that adsorbs the energy of the 
laser. Irradiation with the short-pulsed laser causes mainly ionization of the matrix and 
supports the ionization of the analyte [3]. That is why the MALDI technique can be used for 
the examination of peptides and proteins. 
 
 
1.1.1. General set up of MALDI-TOF instrument 
Ionsource - N2 laser 
Formation of ions and transition into the gas phase are required before the molecular 
masses of a component can be measured with the mass analyser. The generation of intact gas 
phase ions in general, is more difficult for higher molecular mass molecules. The advantage 
of recently discovered soft ionization techniques: MALDI and the electrospray ionization 
(ESI) is that intact gas phase ions are effectively formed from large biomolecules with 
minimal fragmentation [4]. 
In MALDI the sample molecules are co-crystallized with an excess amount of matrix. 
Ionization takes place through protonation in the acidic environments produced by the acidity 
of matrix and also through the addition of dilute acid solution to the samples. Pulses of 337 
nm N2 laser light are used to vaporize small amounts of the matrix and the ions included in 
the sample are carried into the gas phase in the process (Figure A in Appendix).  
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Mass analyzer – Time of flight (TOF) mass analyser 
In Time of flight mass spectrometers the application of the high voltage, typically 
+20kV to +30kV (for positive ions, such as peptides) generates electric field that gives fixed 
amount of kinetic energy to the small pack of the ions. Following the acceleration, the ions 
enter the field-free region, where they travel at a velocity that is inversely proportional to their 
m/z. Because of this inverse relationship, ions with low m/z travel more rapidly than ions with 
high m/z. At the end of the field-free region a detector measures the time of flight (TOF). The 
resolution in a time of flight mass analyser is affected by the instrument and the operating 
conditions. The most remarkable limit on m/z resolution is the range of initial velocities of the 
ions as they are accelerated [4].  
Instead of minimising the effects of the initial kinetic energy of the ions, Wiley and McLaren 
used first the time–lag focusing method, equipped with electron ionization source [5]. The 
delayed extraction (between ~100 nsec to ~500 nsec after the laser pulse) corrects the effect 
of the initial kinetic energy spread by the modification of the ion optics of the time of flight 
m/z mass analyser. Higher-energy ions move farther into the field-free region than lower-
energy ions with the same mass. When the accelerating voltage is applied, it is applied with a 
potential gradient across the source region. The initial energy spread causes a small difference 
in the effective accelerating voltage. This compensates for the initial kinetic energy 
distribution so that ions with the same m/z arrive at the detector at the same time [6]. 
The ion mirror or ion reflector also corrects the effect of the initial kinetic energy spreads on 
mass resolution, created by an electric field that reverses the flight path of the ion. The most 
significant effect of the reflectron is focusing on ions with the same m/z but different 
velocities. Higher-velocity ions penetrate farther, and thereby spend a longer time in the 
reflectron than lower velocity ions.  
When using the combination of delayed extraction and reflectron ion optics, the resolution of 
a time of flight mass spectrometer will increase to >100000. The practical effect of this 
increase in resolution is that monoisotopic peptide molecular weights can be determined as < 
20 ppm (± 0.2 Da for a 1000 Da ion) in commercially available matrix assisted laser 
desorption time of flight mass spectrometers. This type of mass accuracy can have a 
significant effect on the database searches [4, 6]. 
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1.1.2. In-source and post source fragmentation and tandem mass spectrometry 
Proteins from complex biological samples are often identified by mass spectrometry 
(MS) with  
“top-down” strategy, (the investigation of the proteins is carried out without enzymatic 
digestion), the in-source decay (ISD) mass spectrometry is an example 
or 
“bottom-up” approaches: peptide bonds in the protein are cleaved enzimatically and the 
identification of the unknown protein is implemented according to its peptide 
pool/peptide mass fingerprint (PMF) generated by the digestion [7]. 
 
In-source decay (ISD) 
Although MALDI is a soft ionization technique, a significant degree of metastable 
decay can occur along the peptide or protein backbone. The in-source decay (ISD), one of the 
metastable fragmentations is directly observed after the desorption/ionization step in the 
source region [8]. Brown and Lemmon were the first to show the advantages of this procedure 
for analyzing the proteins.  
First, the sample preparation is very simple: the analysis is accomplished without enzymatic 
digestion; the protein is mixed with matrix and directly deposited on the target.  
Second, proteins fragment in three major series ions (cn-, zn-, yn-ions (Figure B in Appendix) 
according to the Roepstoff’s nomenclature) that greatly simplifies the mass spectrum 
interpretation [9, 10]. An N-terminus (and /or C-terminus) sequence tag are rapidly 
determined and used for protein identification in the database. The observed cn, yn produced 
from the fast metastable ion decay process is much different than the fragmentation produced 
from the more widely used post-source decay (PSD) MALDI technique [11]. Formation of bn-
, yn-, an- and xn-ions may occur by increasing the laser power [7]. 
Third, post translational modifications (PTMs) can be studied without loss of the modified 
group as it is often the case in conventional MS/MS. 
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Post-source decay (PSD) 
MALDI was initially described as a “soft” ionization process. In the PSD technique, 
some fractions of the MALDI-generated ions undergo metastable decay during flight by either 
unimolecular or bimolecular (collisions) pathways producing smaller m/z ions and neutral 
molecules. Metastable ion decay occurs after ion acceleration and prior to detection (in the 
first field-free region of TOF analyser). PSD-MALDI fragmentation is typically most 
effective for small and moderate-sized peptides. (In contrast to larger peptides (>5000 Da) 
and even small proteins exhibit sequence-specific ISD fragmentation [12]). The ion fragments 
produced from the metastable ion decay of peptides and proteins typically include both 
neutral molecule losses (such as water, ammonia and portions of the amino acid side chains) 
and random cleavage at peptide bonds [11]. Typical fragmentation observed in PSD-MALDI 
corresponds to an, bn ion series [13] and yn type fragment ions with very small side chain 
specific cleavages (Figure 1). Another common phenomenon in PSD mass spectra is the 
predominance of fragment ions less than 17 Da (an-17, bn-17 series) which is usually thought 
to be due to the loss of ammonia from the N-terminal residue [11]. Mass spectrum in PSD 
mode gives different informative data such as sequence and posttranslational modification 
(PTMs) identification [14-19]. 
 
 
 
 
 
Figure 1: Nomenclature of fragment ions observed in post-source decay (PSD) [7] 
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Tandem Mass Spectrometry 
Mass analysis is essentially a separation of ions according to their m/z. Tandem mass 
spectrometers use this separation as a preparative tool to isolate an ion with a specific m/z for 
further analysis. It is carried out by fragmentation of the mass-selected ion and by the 
determination the m/z of the fragment ions in a second stage mass analysis. The term “tandem 
mass spectrometry” reflects the fact that two stages of mass analysis are used in a single 
experiment. The result is that a specific ion in a complex mixture can be selectively studied in 
an experiment that gives structural information about that ion. In the case of peptide ions, the 
structural information is the amino acid sequence of the peptide [4].  
 
Tandem-in-time instruments: 
Instruments used for performing tandem mass spectrometry experiments in time have only 
one mass analyser (ion trap mass spectrometer) [4]. 
 
Tandem-in-space instruments: 
Instruments in the tandem-in-space category have more than one mass analyser, and each 
mass analyser performs separately to accomplish the different stages of the experiments.  
-“triple quadrupole” mass spectrometer: This type of mass spectrometer contains an octapole 
collision cell between two quadrupole mass filters (mass analyser). 
-quadrupole-time of flight mass spectrometer: This instrument used for protein sequencing 
has a quadrupole mass filter for the first mass analyser and a time of flight mass analyser for 
the second one. 
-reflectron-time of flight mass spectrometer: 
In the reflectron time of flight instrument there is an electrostatic gate used for a precursor ion 
selection. This gate uses voltage pulses to deflect non-selected m/z ions away from the 
entrance to the flight tube. The PSD reactions are fragmentation reactions of metastable ions 
formed by matrix assisted laser desorption, which occur in the field-free region of the TOF 
instrument [19]. In a reflectron instrument that operates in a mass analysis mode, product ions 
from fragmentation are not detected because they are improperly focused by reflectron. 
Measuring the m/z of product ions requires a change of the potentials applied to the reflectron 
to compensate their lower kinetic energies [4, 5].  
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1.1.3. Peptides mass fingerprinting (PMF) and post-translational modification 
(PTM) 
The sequence of the amino acid is unique to each protein and sequence analysis of 
whole proteins by sequential Edman degradation followed by BLAST (database) searching is 
a basic technique for monitoring proteins on proteomic investigation. A sequence of 12-15 
amino acids is often sufficient for an unambiguous identification. However, Edman 
sequencing (specifically remove the N-terminal amino acid from the protein) is too slow (and 
expensive) for routine proteomic analysis and frequently the proteins N-terminally blocked. 
Edman degradation has now been almost entirely substituted by mass spectrometry.  
The determination of the molecular weight of peptides, generated from photolytic or chemical 
digestion of a protein is a so called “mixture analysis” of peptides by mass spectrometry. The 
“MAPPING” of protein structures by soft ionization methods such as MALDI and 
Electrospray have become an important strategy for protein identification and post-
translational modification analysis. New methods have been recently developed using a 
combination of protease digestion, MALDI MS and screening of peptide–mass database that 
offer significant increase in the speed at which proteins can be identified [20]. 
The method involves the generation of peptides from known or unknown proteins using 
residue-specific endoproteinases. All peptides are detected as singly charged ions, and no 
doubly charged peptide ions are observed. All mass values are measured for the monoisotopic 
(M+H)+ ion. The peptide mass profile or fingerprint (PMF) of the query protein can be 
compared with theoretical peptide libraries generated from protein sequence databases to 
produce a list of likely matches. Practical sensitivity extends into the low-femtomole range, 
and three or four masses are often enough to get a significant match in the databases derived 
from more than 100 000 proteins [20]. 
The mass tolerance of the experimental peptides should reflect the accuracy of the mass 
spectrometer being used: typically this is 0.2 Da or 200 ppm or better. Search discrimination 
can be improved by combining results obtained using more than one photolytic enzyme or 
simple chemical cleavage. Increasing the size of the error window the number of the false 
positives will also rise [21]. 
A more important consideration in the use of MALDI analysis is the accuracy of the 
molecular weight measurement. The mass calibration can be implemented with internal 
standard ions (matrix ions and/or trypsin autolysis peptide ions) or external calibration. 
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Good external calibration requires placing the standard sample in close proximity to the 
analyte sample on the sample stage and acquiring the standard spectrum either immediately 
prior to or immediately after the acquisition of the spectrum [4, 6]. 
 
Post-translational modification (PTM) 
The ability of mass spectrometry to characterize post-translational modifications is 
also unique among the protein and peptide sequencing methods and this use has been 
described as a vital contribution of mass spectrometry to polypeptide characterization.  
By definition, a post-translational modification of a protein is any modification of the protein 
structure that occurs after the synthesis by translation of the messenger RNA. Post-
translational modification of a protein, however, is most often envisaged as a change made to 
the structure of the side groups of specific amino acid residues contained in the protein. 
Mostly, no such modifications are expected for the aliphatic amino acids (glycine, alanine, 
valine, leucine and isoleucine) or the aromatic amino acid (phenylalanine). For the other 
amino acids, however, the presence of amine, carboxylic acid, hydroxyl, thiol, and thioether 
functional groups creates reactive sites that are vulnerable to a wide variety of chemical and 
biochemical reactions that can occur in the active milieu of the biological system. A common 
characteristic of these modifications is that the change made in the amino acid structure, 
produces a corresponding change in the amino acid residue. This change of formula weight 
constitutes the basis of the detection and characterisation by mass spectrometry [22]. 
 
1.1.4. Different on target sample preparation approaches 
The function of the matrix is to dilute the sample, absorb the laser energy and ionise 
the sample. Each pulse from the laser vaporises both sample and matrix from the surface of 
the target and catalyses a chemical reaction which, in the positive ion mode, results in a 
proton [M+H]+ or alkali metal atom being attached to the sample molecules. In the negative 
ion mode, the ionic species produced is usually [M- H]- [23]. 
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Matrices: 
The matrix is important in MALDI analysis because it serves both as laser energy 
absorbent and for energy transport. The matrix also separates the analyte molecules from each 
other, anticipating cluster formation and obviating direct laser “hit” that would effect intense 
peptide fragmentation [24]. Matrices can be small aromatic acids. The aromatic groups absorb 
at the wavelength of the laser light, while the acid helps the ionization of the sample 
molecules [4, 6]. A great variety of matrices are available. 
 
A “good” matrix should meet several requirements: strong absorption at the laser wavelength, 
being a good solvent for the analytes, resulting in homogenous co-crystallisation. 
 
Frequently used MALDI matrices: 
sinapinic acid (SA) 
A large number of matrices have been investigated by Beavis and Chait and sinapinic 
acid [21] has been found to be the best for larger ions giving better signals accordingly. This 
compound is preferred for the ionization of larger proteins and glycoproteins [25]. 
 
2,4,6-trihydroxyacetophenone (THAP) 
Trihydroxyacetophenone has been thought to be the best matrix for analysing 
glycoproteins and glycopeptides, because it provides low limit of detection and gives less 
prompt fragmentation. THAP offers improved sensitivity for detection of acidic glycopeptides 
over alpha-cyano-4-hydroxycinnamic acid (Figure 2/d) [26]. 
 
α-cyano-4-hydroxycinnamic acid (CHCA) 
For smaller proteins, α-cyano-4-hydroxy-cinnamic acid [27] is preferred [23], 
although CHCA forms small crystals that are unevenly distributed over the sample surface, 
i.e.; areas with lower crystal densities at the centre of the preparation (Figure 2/a) [25, 28]. 
 
2,5-dihydroxybenzoic acid (DHB) 
DHB is better suited for analysing glycopeptides in combination with dried droplet 
technique than any other matrices [26]. Typically DHB tends to crystallise from the periphery 
of the target spot in the form of long needles that point towards the centre of the target (Figure 
2/b) [23, 28, 29]. 
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Various sample preparation methods are available: 
dried-droplet method: 
0.5–2 µL of sample and 0.5–1 µL of matrix solution (8 mg×mL-1-saturated solution) 
(CHCA, SA, DHB, THAP) are mixed on the target and allowed to dry in the ambient air 
(slow crystallization technique), or optionally, in a gentle stream of forced air or argon (rapid 
crystallization method) (Figure 2) [25]. 
 
Thin layer method: 
A thin layer of small, homogeneous matrix crystals is made on the target by placing 
either 0.5–1 µL of CHCA or 0.5–1 µL of THAP (2 mg×mL-1) onto the target and the droplet 
is allowed to spread and dry, after that 1 µL of sample is added to the thin layer of crystalized 
matrix [25]. 
 
Mixed matrix: 
In practice, one matrix may not meet the requirements mentioned above at the same 
time for the diversity of analytes in a sample, so co-matrices formed by the use of a suitable 
additive in the matrix solution are often used. 
The combination of two common matrices (CHCA and DHB) mixed in dried droplet 
preparation was written as an excelent co-matrix. Combination of the matrices showed better 
crystal distribution with DHB-like crystals forming short needles at the rim and evenly 
distributed CHCA-like crystals inside the rim [28]. Combination of CHCA and DHB results 
in increased surface homogeneity and spot-to-spot reproducibility, increased signal-to-noise 
ratio and tolerance to impurities [28]. 
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(d) THAP 
 
Figure 2: a) CHCA b) DHB c) Matrix mixture [28] d) THAP [26] 
Microphotographs obtained with a) CHCA b) DHB d) THAP and c) mixed matrix 
preparations in the dried-droplet method. 
 
 
1.2. Desalting of proteins and peptides by solid phase extraction (SPE) 
An important prerequisite of the MALDI-TOF/MS measurements is the removal of 
disturbing compounds; e.g. salts from the buffer or urea, guanidine hydrochloride after 
proteolysis [29]. 
SPE is an easily applicable method most frequently used for desalting, purification, 
preconcentration and fractionation of a complex mixture of peptides [30-32]. Fractionation 
prior to analyses can have a significant effect on sequence coverage of proteins particularly 
implemented for those peptides obtained from the proteolysis of larger proteins [24]. Further 
advantages of the SPE method include relatively high recovery rate, short extraction time, 
high enrichment factor and low consumption of organic solvents [33, 34]. 
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1.2.1. SPE packings often used in bioanalytical investigations 
The classical commonly used sorbents are porous silica-based particles surface-
modified with C18 or other hydrophobic alkyl groups such as C4, C14, C30. The Oasis from 
Waters and the Abselut from Varian are available from polymer monolithic columns. 
 
1.2.1.1 Silica based phases 
The most widely used SPE materials in the field of bioanalytical research are silica-
based C18 reversed phase sorbents, since the introduction of Sep-Pak cartridges in 1978 [34] , 
despite some drawbacks of using alkylated silica (low recovery for basic analytes, relatively 
low capacity and poor wettability, etc.) [35]. 
 
1.2.1.2 Polymer based resins 
The new generation of polymers (Oasis from Waters, Abselut from Varian) are 
developed to extract widespread spectrum of analytes, i.e., lipophilic, hydrophobic, acidic, 
basic and neutral with a single cartridge with a simplified procedure (no conditioning is 
required) [36]. The polymer beads in the extraction cartridge can be used from pH 1 to 14 (in 
contrast to classical reversed phase silica extraction columns) and with many different polar 
and apolar organic solvents (methanol, chloroform, diethyl ether, etc.). Therefore, when using 
polymer sorbents, it is easier to find an appropriate extraction condition for specific 
compounds and especially for mixture of analytes with different chemical properties [37]. 
By the introduction of Oasis HLB sorbent prepared by the copolymerization of lipophilic 
divinylbenzene and hydrophilic N-vinylpyrrolidone the flowthrough of some polar 
compounds, the undesirable effect of silanol groups and the poor wettability in water were 
eliminated [38]. Another important SPE medium is the AbselutTM, which is a blend of 
methacrylic ester-based polymeric and polystyrene resin mixed in a particular ratio [37].  
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1.2.1.3 Novel stationary phases for SPE  
Fullerene 
Fullerenes, allotropic forms of carbon were discovered in 1985 [39] and they can be 
considered as a well-characterized nanostructure [40]. The use of C60 or a mixture of C60 
and C70 fullerene has increased. Many different applications of fullerenes have been reported 
in analytical chemistry for preconcentration purposes due to its good stability, wide pH range 
for working conditions, and high surface area [41]. 
 
Fullerene derivatized silica - C60 silica 
 Hydrophilic peptides like phosphopeptides and glycopeptides can be retained and 
purified on neither RP silica particles nor polymeric SPE resins mentioned above. For the 
purification and enrichment of such molecules the preparation and application of 
fullerene(C60)-silica (Figure 3) have been recently described [42]. Fullerene(C60)-silica can 
be prominent SPE sorbent material, showing reversible interactions with analytes with low 
masses such as flavonoids and peptides. These newly developed fullerene-derivatized silica 
materials are compared with some already obtainable SPE materials on the market. C60-silica 
has proven to have excellent features toward SPE applications with different molecules [42]. 
 
 
 
Figure 3: structure of the fullerene silica [42] 
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1.2.2. On-line and off-line solid phase extraction 
The principles of HPLC and SPE are similar: adsorption and distribution of analytes 
between the mobile and stationary phases. The surface chemistry of the particles is mostly 
based on C18 modified silica and the design of SPE cartridges is similar to chromatographic 
columns. 
 
On-line solid phase extraction: 
Two approaches (to improve throughput and reliability of the analytical method) have 
been developed to automate solid phase extraction. It is required to employ a robotic system 
to automate the sample preparation using traditional desalting devices or extraction plates. 
The sample is loaded and concentrated onto a modified SPE device (capable of high-pressure 
operation) which is located at the injection sample loop. The undesired components are 
washed off the SPE cartridge to waste by the mobile phase. Afterwards a valve is switched 
and the required components of the SPE device is eluted on to the analytical column and the 
sample can be analysed by a mass spectrometric instrument [30]. 
 
Off-line solid phase extraction:  
Modern solid phase extraction is most often based on alkyl surface modified silica. 
The instrumental design of SPE is similar to a small chromatographic column, although off-
line SPE devices vary from chromatographic columns in such features: 
(i) off-line SPE devices are disposable, made for a single use only 
(ii) SPE devices are packed with larger particle size sorbents (30-100µm), while HPLC 
columns are filled with 3-5µm particles. 
(iii) the length of SPE devices are smaller than that of the HPLC columns 
(iv) SPE devices can easily be loaded and can elute the sample into diverse collection 
devices 
(v) there is significant dead volume of the SPE devices 
(vi) SPE devices ensure considerably lower chromatographic efficiency than HPLC columns 
[30]. 
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The two most popular applications for SPE:  
One is when the analyte is derived from biological liquids and drugs of interest are retained 
on the sorbent, as long as most of the protein components are eliminated to the waste by the 
washing solution (aqueous buffer). 
The other common use of the SPE is desalting peptides or DNA oligonucleotides. While 
these required sample molecules are retained on the sorbents, non-volatile salts are washed off 
the sorbent with pure water [30]. 
The choice of the pH and the mobile phase strength is crucial for the best SPE selectivity 
because of the strength of the possible washing solvent to eliminate the interfering 
components without loss of desired analyte. The convenient pH is selected for suppressing in 
analyte ionization, because the non-ionized form of the analytes are much more strongly 
retained on reversed phase sorbents.  
 
Microextraction methods: 
Miniaturization of sample pre-treatment was a current trend in the last years. This 
derived from several factors: 
• The available sample amount is limited (proteins isolated from gel slabs, single cell 
analysis). 
• Some samples may be expensive 
• Miniaturized techniques (capillary electrophoresis (CE) and capillary HPLC) require less 
than a few microliters for analysis 
• Miniaturization of sample clean-up apparatus allows for parallel processing of samples for 
high throughput. 
This trend of biological sample processing leads to smaller sample volumes and higher 
sample enrichment efficiency [30]. 
Miniaturized solid phase extraction tips are packed with a small amount (0.1mg) of reversed 
phase material or other sorbent, which allows eluting the desired components in small volume 
of mobile phase [30]. Microscale SPE has been developed for MALDI-TOF/MS [43] and off-
line nano-electrospray (ESI) MS [44]. 
To fulfil the requirement, pipette-like tips were manufactured using small amounts of sorbent 
trapped in plastic tips [45]. Prior to analysis, the peptides/proteins can be preconcentrated or 
selectively captured employing tips packed with particles with different affinities (normal 
phase, RP silica, ion exchanger or resins provided with affinity chromatography, molecular 
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imprinted stationary phases, restricted access sorbents or mixed mode sorbents). The 
extensively used ZipTips (C18-silica) (Millipore, Bedford, USA) is similar to a 10µl 
micropipette tip with a bed volume of 0.55 µl. Sample volumes of 2-4 µl can be processed 
with a capacity of up to 15µg for peptides [46].  
 
 
 
 
 
1.3. Boronate affinity chromatography 
Boric acid and boronic acid are well known to form stable esters with polyols and 
saccharides containing cis-diol groups [47]. Increased attention has been paid to these 
compounds because of their prospective applicability to recognize sugars [48]. 
Boronate affinity columns were first used for the separation of sugars, polysaccharides and 
nucleic acid components by Weith et al in 1970 [49]. Up till now this method has been 
adopted ubiquitously for the separation of cis-diol compounds such as nucleosides, 
nucleotides, nucleic acids, carbohydrates, enzymes, glycated proteins, glycated peptides. This 
method is described as a useful separation technique for the measurement of 
glycohemoglobin, the study of the glycation pattern of hemoglobin, the determination of 
hemoglobin HbA1c in diabetic patients, the purification of arginine containing peptides and 
the separation of glycoproteins and glycopeptides [50]. 
 
1.3.1. Interactions between immobilized boronate and analytes 
Primary interactions: 
The most important interaction in boronate affinity chromatography is the 
esterification that exfoliates between a boronate ligand and a cis-diol containing compound. 
Ideally, this ester bound requires that the two hydroxyl groups of the diol be adjacent carbon 
atoms and in an approximately coplanar configuration. If the interactions between boronates 
and 1,3-cis-diols or trident interactions between boronates and cis-inositol or trietanolamine 
occur, they give weaker ester bonds than those between the 1,2-cis-diols and the boronates. 
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The interaction occurs in aqueous solution under basic conditions, the boronate is 
hydroxylated and then it can form cyclic diesters with cis-diols. The formed esters can be 
hydrolysed under acidic conditions. This reaction is reversible in aqueous solution (Figure 4) 
[51]. 
 
 
 
 
Figure 4: Mechanism of binding and elution processes between cis–diol-containing 
compounds, for example Amadori peptides and boronic acid [51]. 
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 While using boronate affinity chromatography, secondary interactions (especially 
hydrophobic and ionic interactions) must be considered.  
 
Secondary interactions: 
Four types of secondary interactions can occur on boronate affinity material: 
hydrophobic interactions, ionic interactions, hydrogen bonding and coordination interactions. 
 
Hydrophobic interactions: 
Most of the used boronate affinity ligands are aromatic boronates. These include a 
phenyl ring that could give rise to hydrophobic interactions or aromatic π-π interactions. 
Hydrophobic interactions could give an additional selectivity to the column. Hydrophobic 
interactions are sometimes responsible for the nonspecific binding of undesired proteins or 
peptides. This phenomenon can entirely be avoided by adding detergents to the mobile 
phase/binding buffer [50, 52]. To reduce hydrophobic influences in the boronate affinity 
chromatography is to keep the ionic strength of the mobile phase low. 
Ionic interactions: 
The active tetrahedral boronate is negatively charged therefore boronate ligands can 
create coulumbic attraction or repulsion for ionic analytes. Generally, this effect is weaker 
than boronate/cis-diol ester formation. Ionic interactions between the negatively-charged 
boronate and anionic proteins can hinder the necessary binding; this is why Mg2+ ions at low 
concentrations are to be added to the mobile phase/binding buffer in order to eliminate the 
undesirable ionic effects [50, 52]. As in hydrophobic interaction, ionic interactions can cause 
additional selectivity for boronate affinity separation. To decrease ionic effects, the ionic 
strength of the mobile phase should be kept high, although this will also effect stronger 
hydrophobic interactions.  
Hydrogen bonding: 
Since boronic acid has three hydroxyls in the active tetrahedral form (or two in the 
non-active form) it has several possibilities for form hydrogen bonds. Although the effect of 
this possible interaction is usually small, under special condition hydrogen bond bonding 
could be strong enough to be the main mechanism for retention on a boronate column. 
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Coordination interactions: 
In the non-activated trigonal uncharged boronate molecule the boron atom has an 
empty orbital; this could attend as an electron pair acceptor for a coordination interaction. In 
the sample the unprotonated amines are perfect electron pair donors and when an amine 
donates a pair of electrons to the boron atom, the boronate molecule becomes tetrahedral. This 
explains why amines may attend to promote boronate/cis-diol esterification. However, if there 
is a hydroxyl group adjacent to the amine, this hydroxyl group could interact with the 
tetrahedral boronate. This interaction could prevent the esterification between the boronate 
ligand and the analyte. For this reason it is required that TRIS 
(tris(hydroxymethyl)aminomethane) and ethanolamine derivatives be avoided in buffers used 
for boronate affinity chromatography [50]. 
 
1.3.2. Types of stationary phases of boronate affinity chromatography 
Boronate can be employed as a matrix which can selectively bind the glycol moieties 
through covalent binding with a 1,2-cis-diol of glycostructure. Zhou et al. [48] prepared 
aminophenylboronic acid-functionalized magnetic nanoparticles and successfully applied 
them to selective separation in proteomics; in addition, Xu et al. [50] have successfully 
utilized boronic acid-functionalized mesoporous silica to enrich glycopeptides. Potter et al. 
[53] and Ren et al. [54] reported using boronate monoliths for affinity separation and 
capturing of cis-diol containing compounds, respectively. 
 
Carboxylic acid terminated magnetic beads 
Recently, magnetic beads have been used for immobilization of aminophenilboronic 
acid and applied for the specific binding of cis-diol containing compounds. Since these 
magnetic beads can be washed and separated easily with an external magnetic field, the use of 
phenilboronic acid immobilized magnetic beads is a very efficient method for the sample 
preparation of glycoproteins, glycopeptides and glycated peptides for mass spectrometry, 
especially for MALDI measurement [55]. 
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Agarose beads 
The application of the immobilized phenylboronic acid on agarose and sepharose 
hydrogel microparticles, which are deposited on an aluminium chip, enabled the high 
throughput analysis of AGEs from serum sample by MALDI–MS. One of the most 
advantageous features of the microchip is that no elution of the bound molecules is required 
[56]. 
 
Silica based boronate affinity chromatography 
Boronic acid functionalized mesoporous silica, which preserves the attractive features 
of high surface area and large accessible porosity, was developed to enrich cis-diol 
compounds, e.g. glycopeptides. Boronic acid functionalized mesoporous silica has a 
comparatively large specific surface area, so it could adsorb glycopeptides fast and efficiently. 
Its other great advantage that is easy to recover by centrifuge in order to extract glycopeptides 
from the peptide pool effectively. [57] 
 
polymer monolith as a stationery phase in boronate affinity chromatography 
Recently the boronic affinity chromatography was combined with monolithic 
stationary phase by Potter et al. in 2006 [53]. Monolithic beds can be described as an 
integrated continuous porous separation media without interparticular voids [58]. This 
combination of boronate affinity chromatography with monolithic column format offers better 
performance and more functions for the analysis of cis-diol-containing compounds. Besides, it 
avoids non-specific interactions, especially reversed phase interaction. The optimization of 
these new-generation columns has not been executed, and unfortunately, the literature of 
boronate functionalized monolithic columns is still in progress [58, 59, 60]. 
 
1.3.3. Application of boronate affinity in the field of proteomics 
Boronate affinity columns were first used for the separation of sugars, polysaccharides 
and nucleic acid components by Weith et al in 1970 [49]. The application of the boronate 
affinity column in proteomics for the separation and quantification of glycohemoglobin was 
published by Mallia et al. in 1981. A low–performance agarose gel was applied as the support 
and absorbance detection at 414 nm was used to quantify the retained and non-retained 
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hemoglobins in human hemolysate samples. Elution was carried out by a soluble diol-
containing agent (sorbitol solution) that eluted the retained glycohemoglobin from the 
column. 
Up till now this method has been adopted ubiquitously for the separation of cis-diol 
compounds such as nucleosides, nucleotides, nucleic acids, carbohydrates, enzymes. This 
method is described as a useful separation technique for the quantitative measurement of 
glycohemoglobin [61], the study of the glycation pattern of hemoglobin, the determination of 
hemoglobin HbA1c in diabetic patients, the purification of arginine containing peptides, the 
separation of enzymes [47, 48] glycoproteins and glycopeptides glycosylated proteins [24, 62-
66] and glycosylated peptides [50, 59, 67, 68]. 
 
 
 
1.4. Non-enzymatic glycation  
Non-enzymatic glycation is the covalent binding of single reducing sugars to amino 
groups in proteins. The initial product is a labile Schiff base intermediate, which slowly 
isomerises to form a stable ketoamine, called Amadori compound (AC). The AC can undergo 
further oxidation rearrangement reactions to form a series of more reactive, coloured, 
fluorescent compounds, termed advanced glycation end-products (AGEs), which play a 
pathogenic role in the development of diabetic complications [69]. 
 
1.4.1 Non-enzymatic glycation of proteins 
Formation of Schiff base and Amadori compounds 
The non-enzymatic reaction of the amino groups of amino acids, peptides and proteins 
with reducing sugars was first studied under defined conditions in the early 1900s by L. C. 
Maillard [70]. Non-enzymatic glycation is the covalent binding of single reducing sugars 
(glucose, fructose, ribose, etc.) to primary amino groups in proteins, such as the ε-amino 
group of the protein lysine residue (Figure 5) [71, 72, 73]. The initial product of Maillard 
reaction is a labile Schiff base intermediate [64, 74]. In the 1920s Amadori showed that the 
Schiff bases could be converted to isomeric products via an intermediate, an open-chain enol 
form (Figure 5) by the Amadori rearrangement [75]. In the reaction the labile adduct slowly 
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isomerizes and therefore forms a stable ketoamine, called the Amadori compound (AC) [74, 
76] (83). To simplify the discussions of the Maillard reactions, the adducts are frequently 
depicted as the more reactive open-chain forms. Formation of the Schiff base is relatively fast 
and highly reversible and the formation of the Amadori product from the Schiff base is 
slower, but much faster than the reverse reaction, so that the glycation product tends to 
accumulate on proteins [64, 72]. 
 
 
 
Figure 5: Formation of the glucose-protein Schiff base and the Amadori rearrangement [64] 
 
 
Advanced Glycation End products (AGEs) 
The AC can undergo additional oxidation and rearrangement reactions and eventually 
dehydration, condensation, fragmentation, oxidation and cyclization reactions to form a series 
of biologically considerably more reactive constituents, termed advanced glycation end-
products (AGEs) [74, 77].  
 Different types of AGEs are known, depending on the compound they originate from. 
Six distinct classes of AGEs were recognized deriving from glucose (AGE-1), from other 
carbohydrates, such as glyceraldehydes (AGE-2), and from α-dicarbonyls, such as 
glycoaldehyde (AGE-3), methylglyoxal (AGE-4), glyoxal (AGE-5), 3-deoxyglucosone 
(AGE-6) by Takeuchi et al. in 2004 [78]. All these compounds can react with the amino group 
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of lysine of the terminal amino group of proteins and with the guanidine group of arginine and 
also with cystein. Moreover, AGEs can generate crosslinks in proteins [79], free radical 
reactions that might catalyze further damaged proteins, lipids or DNA [72].  
 
1.4.2. Physiological importance of non-enzymatic glycation 
As a result of the non-enzymatic glycation the above mentioned types of AGEs can be 
formed because of the increased blood glucose level in hyperglycaemia, diabetes mellitus 
types I and II. However, the total biochemical pathway between chronic hyperglycaemia and 
functional alterations and tissue damage are still incompletely understood. There are several 
candidate mechanisms for explanation: such as, the increase in non-enzymatic glycation of 
proteins, with irreversible formation and deposition of AGEs and the increased oxidative 
stress (possibly caused by the presence of the increased level of the AGEs) [79]. 
Three core reactions of AGE damage were described as follows: interactions with specific 
receptors, intracellular accumulation and abnormal crosslink formation.  
Until now, crosslink formation, especially at collagen level was thought to be the most 
important mechanisms of the AGE damage, as well as the physical and chemical 
modifications of collagen causing abnormal vascular rigidity, arterial stiffness, basement 
membrane thickness [74, 80]. On the other hand long-lived proteins, such as lens crystalline, 
collagen of the extracellular matrix, serum albumin and haemoglobin accumulate AGEs in 
vivo [72]. 
Diabetes is an extensive disease, affecting 4% of the whole world population. For this 
reason, great efforts have been made to optimize the control of the acute complications of the 
disease (hypoglycaemic coma, ketoacidosis, and infections), but the long-term complications 
of the diabetes such as macroangyopathy, vasculopaty, immunodeficiency, nephropathy, 
retinopathy and neuropathy, which still remain widely spread [81, 82]. 
 
1.4.3. Clinical methods used for the detection of non-enzymatic glycation 
Since the 1970s, the measurement of glycated hemoglobin A1c (HbA1c) has been 
used routinely as a clinical diagnostic marker for relatively long term (4-6 weeks) glucose 
control in diabetic patients [63]. In order to find more specific and informative protein 
biomarkers for monitoring the glycemic state and to get a deeper insight in the role of 
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glycation in the development of diabetic complications comprehensive proteomic studies are 
required. 
The level of the glycated albumin in serum is thought to represent the condition of the blood 
glucose over the last 2 to 4 weeks, while HbA1c indicates glycaemia state over the last 1 or 2 
months [65]. Glycated human serum albumin (HSA) is an important midterm indicator of 
diabetes that is more sensitive to changes in blood glucose level than HbA1c [64]. The 
glycated albumin level also provides useful information on glycaemic control when 
monitoring the efficiency of therapy [65]. 
Recently, the main techniques investigating the glycation of proteins have been based on a 
variety of on- and off-line mass spectrometric methods (LC coupled to MS, CE or LC 
separation/fractionation-MALDI MS, etc) [24, 66, 67, 68]. Although a great number of 
studies deal with the examination of glycation as well as with the methodological 
development concerning the investigation of glycated constituents, there is a need to improve 
the existing methods or to develop novel, more sufficient and less time consuming techniques. 
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2. Aims 
 
2.1 Development in the application of Solid Phase Extraction: 
I. Determination of the binding capacity of C30 and C60(30) fullerene silica with Leu-
enkephalin 
 
II. Identification of C18, C30, C60(10), C60(30) and C60(100) on the sequence coverage of 
the tryptic digests 
 
III. Determination of glycated sites of Human Serum Albumin (HSA) and fibrinogen with 
C30 and C60(30)-silica  
 
 
2.2 Experiments of boronate affinity chromatography for the separation of 
glycated peptides: 
IV. Optimization of different approaches of elution in the case of boronate affinity tips. 
 
V. Desalting of glycated peptides using different sorbents 
 
VI. Application of the new method for the detection of glycated peptides obtained from 
digested human serum albumin, collected from patients suffering from type 2 diabetes–
compared to that of healthy volunteers 
 
  28 
3. Materials and methods 
3.1 Materials and methods in the case of solid phase (SPE) experiments 
The first part of this chapter of the thesis includes the instrumentation and the 
documentation of the research on the optimization of the solid phase extraction method for 
glycated peptides. 
3.1.1 Materials 
C60-fullerene (≥99.5 %) was bought from MER Corp. (Tucson, AZ, USA). Acetonitrile, 
methanol (both gradient grade), human serum albumin (HSA, 97-99%), fibrinogen (fraction I, 
type I: from human plasma, 67 % protein), Leu-enkephalin acetate hydrate (≥97 %), [Arg8]-
Vasopressin acetate salt (≥99 %), angiotensin I human acetate hydrate (≥90 %), trifluoroacetic 
acid (≥99%), α-cyano-4-hydroxycinnamic acid (CHCA, ≥99 %), 2,5-dihydroxybenzoic acid 
(DHB, ≥99%), 2’,4’,6’-trihydroxyacetophenone monohydrate (THA ≥99.5 %), sinapinic acid 
(SA, ≥99%), D/L-dithiothreitol (DTT, >99 %), iodoacetamide (≥98 %), 2-mercaptoethanol 
(≥98 %), ammonium bicarbonate (>99 %), 3-chloroperoxybenzoic acid (70-75 %) and 
(aminopropyl)trimethoxysilane (>97 %) were purchased from Sigma-Aldrich (Budapest, 
Hungary). D-glucose monohydrate (puriss), urea, toluene (>99 %) and tetrahydrofuran (>99.8 
%) were from Reanal Finechemical Co. (Budapest, Hungary). Formic acid (98-100%) was 
bought from Scharlau Chemie S.A. (Barcelona, Spain). Peptide calibration standard 
(consisting of bradykinin, angiotensin II, angiotensin I, substance P, renin substrate, ACTH 
clip (1-17), ACTH clip (18-39) and somatostatin) and protein calibration standard (consisting 
of trypsinogen, protein A, BSA, BSA-dimer) were obtained from Bruker Daltonics (Bremen, 
Germany). Trypsin (sequencing grade, modified) was provided by Promega Corporation 
(Madison WI, USA). Bidistilled water was prepared in our laboratory.  
 
3.1.2 Instrumentation 
Autoflex II MALDI instrument from Bruker Daltonics was used for the mass 
spectrometric measurements.  
The HPLC instrument consists of a Dionex P680 gradient pump, Rheodyne 8125 injection 
valve, a Dionex UVD 340U UV–Vis detector (Dionex, Germany). Data acquisition was 
carried out using the Chromeleon software (version: 6.60 SP3 Build 1485). 
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A Jasco V-550 UV–Vis spectrophotometer (Tokyo, Japan) was employed for measuring the 
adsorption spectra of SPE materials. 
Pore size and pore volume of the phases were measured employing mercury intrusion 
porosimetry method (Porosimeter 2000, Thermo Finnigan, San Jose, USA). 
Elemental analysis of all the investigated phases was implemented by a Carlo Erba EA 1110 
CHNS instrument (Rodano, Italy). 
The specific surface area of the phases was determined by BET method using a homebuilt 
device [42]. 
 
3.1.3 Preparation of the SPE phases 
For the SPE experiments C18 and C30 RP materials were synthetised from Kovasil 
silica gel according to the method described by Szabó et al. [83]. The C60(fullerene)-
derivatised silica particles, (prepared, described and characterised by Vallant et al.) [42] were 
made from three different silica gels with distinctive characteristics in order to study the 
effects of porosity. The amino groups remained on C60-derivatives after the first 
derivatisation considerably shielded by the bulky C60 balls (Figure 3); therefore the phase 
behaves RP rather than normal phase. Moreover, the protonated NH3+ groups repulse the 
protonated, positively charged peptides. So they are not supposed to be well accessible to the 
peptides.  
3.1.4 In-vitro glycation of HSA and fibrinogen 
HSA (Sigma-Aldrich) (5 mg) was dissolved in D-glucose solution (0.167 M in 
phosphate buffered saline (PBS), pH 7.4) [81]. Fibrinogen (Sigma-Aldrich) does not dissolve 
in water; therefore 2 mg of protein was layered on top of warm (37°C) saline solution (0.9% 
m/v) consisting of D-glucose at a concentration of 0.167 M [84]. This solution was gently 
agitated till the material was dissolved and then it was further diluted with PBS buffer 
(containing D-glucose at a concentration of 0.167 M) in 1:1 ratio. Solutions of both proteins 
were incubated under aseptic conditions for 28 days at 37°C. Before further modifications and 
tryptic digestion the glycated HSA and glycated fibrinogen were purified by centrifugation 
through a membrane (Millipore, cut-off: 3000 Da). 
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3.1.5 Tryptic digestion of nonglycated and glycated HSA and fibrinogen 
HSA (1 mg) or fibrinogen (1 mg) was dissolved in 500 µL of denaturing buffer 
consisting of 8 M urea and 0.5 M ammonium bicarbonate, and was shaken for 30 min, at 
37°C to denature the proteins. DTT (50 µL, 30 mM) solution was added to break the 
disulphide bonds (37°C, 4 h). After the solution was cooled down, 25 µL 100 mM 
iodoacetamide solution was added for 15 min in darkness to alkylate the cysteines. The 
reaction was stopped by the addition of 50 µL 100 mM 2-mercaptoethanol and the mixture 
was kept at ambient temperature for 15 min. Then the solutions of both proteins were put into 
a Microcon-YM3 centrifugal filter tube (Millipore) and centrifuged at 13000 × g for 4 h. This 
assured the removal of excess chemicals through the membrane (cut-off: 3000 Da). The 
residues of the modified proteins were digested with trypsin to a protein ratio of 1:100 in 50 
mM ammonium bicarbonate solution overnight at 37 °C. The digestion was stopped by 
evaporation under vacuum and the resulting digest was redissolved in 5 µL water. The same 
protocol was used for the glycated proteins. Figure 6 shows the photolytic digestion by trypsin 
[85].  
 
 
 
Figure 6: cleavage by trypsin 
 
Trypsin is known to cleave proteins at the carboxyl side of the arginine and lysine residues 
except those that have a proline at their C-terminal end [67]. 
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3.1.6 Recovery study of the phases 
Into five 1.5 mL volume SPE cartridges (Alltech Extract-CleanTM SPE 1.5 mL 
Reservoir, Alltech Associates, Deerfield, USA) 5 mg from each SPE material was placed and 
sealed with Teflon frits. All materials were washed with 2 mL tetrahydrofurane (THF), and 
then with 1 mL methanol to eliminate the contaminants that might have ensued from the 
derivatization. This was followed by an activation step; using 2 mL acetonitrile (ACN) 
containing 0.1% trifluoroacetic acide (TFA). Then the particles were rinsed with 2 mL of a 
0.1% TFA in 50% ACN and the cartridges were equilibrated with 2 mL 0.1% TFA in water. 
Solutions (200 µL) consisting of three peptides (Leu-enkephalin, [Arg8]-vasopressin and 
angiotensin I) in different concentrations (10, 30, and 50 µg from each) were loaded onto the 
equilibrated cartridges. The permeate was collected and the cartridge was washed with 0.1% 
TFA in water. The bound peptides were eluted with 300 µL 50% ACN containing 0.1% TFA. 
To ensure the complete and quantitative removal of peptides the elution step was repeated and 
the two fractions were combined. The solvent from the breakthrough and the eluates were 
evaporated under vacuum, the remaining peptides were redissolved in 1 mL 0.1% TFA in 
water and the solution of the peptides was analysed with HPLC. The separation of the three 
peptides was carried out on a Kovasil ODS (C18) column using gradient elution. Eluent “A” 
was 0.1% v/v TFA containing 5% v/v ACN, while eluent “B” 0.1% TFA in 95% v/v ACN. 
The gradient profile was: 0–6 min: 0% “B” → 20% “B”, 6–20 min: 20% “B” → 38% “B”, 
20– 22 min: 38% “B” → 60% “B”, 22–24 min: 60% “B”. The flow rate was: 1.2 mL×min-1. 
Chromatograms were monitored at 214 nm [85]. 
 
3.1.7 Adsorption of peptides on C30 and C60 silica 
After the activation and equilibration, 3 mg of both C30-silica and C60(30) were incubated 
overnight with a solution of Leu-enkephalin (0.1% TFA in water) at different concentrations 
ranging from 60 to 210 µg/mL under vigorous shaking at 20°C. Then the particles were 
centrifuged and the supernatants were analysed.  
 
3.1.8 SPE of the digests 
The tryptic digest (20 pmol) from HSA and fibrinogen in 200 µL 0.1% TFA/water 
were loaded onto the equilibrated particles, and the SPE tubes were washed three times with 1 
mL 0.1% TFA/water to remove the non-bound peptides. The peptide pool was fractionated 
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gradually with 5–70% v/v of ACN/water with 0.1% TFA, increasing the ACN concentration 
of the eluents with 5% in each step. From each eluent 300 µL was used. Fractions were 
collected, evaporated, redissolved in 5 µL water and analysed by MALDI-TOF/MS. For the 
fractionations of the glycated protein digests the same procedure was done.  
 
3.1.9 Enrichment of the glycated peptides using boronate affinity tips  
Pipette tips containing 5 µL gel of immobilized m-aminophenylboronic acid with a 
total volume of 200 µL (PhyTip 1000+ columns, PhyNexus, San Jose, USA) were used for 
the enrichment of the glycated peptides. After rehydration the tips were equilibrated with 
binding buffer (150 mM NH4Cl and 50 mM MgSO4 at pH 8.2). Glycated peptides were 
diluted with the binding buffer and the solution was aspirated through the affinity gel. Then 
the tips were washed with 1 mL of binding buffer to remove unselectively bound peptides, 
and with bidistilled water to get rid of the residues of buffer constituents. Glycated peptides 
were eluted with 4x50 µL formic acid solution at pH 2. 
 
3.1.10 Preparation of different MALDI matrices 
Three different matrices were compared for the ionisation of peptides. 2,5-
dihydroxybenzoic acid (DHB) was prepared in 20% v/v ACN /0.1% TFA/ water at a 
concentration of 25 mg×mL-1. 
Saturated solution of α-cyano-4-hydroxycinnamic acid (CHCA) was prepared in a mixture of 
water and ACN 2:1 ratio containing 0.1% TFA. 
2’,4’,6’-trihydroxyacetophenone monohydrate (THAP) was dissolved at a concentration of 15 
mg×mL-1 in 50% v/v ACN / 0.1% TFA/water.  
The saturated solution of sinapinic acid (SA) was prepared in 50% v/v ACN and 0.1% TFA in 
water for the ionization of proteins. 
 
3.1.11 MALDI-TOF/MS analysis 
All mass spectra were acquired in positive mode with pulsed ionisation (k = 337 nm; 
nitrogen laser, maximum pulse rate: 50 Hz; maximal intensity 20–30% of the laser for 
peptides). Tryptic peptides were measured in reflectron mode using a delayed extraction of 
120 ns and were monoisotopically resolved.  
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Proteins were measured in linear mode at a delayed extraction of 550 ns. The accelerating 
voltage was set to +19 kV, the reflectron voltage was set to +20 kV. Spectra of peptides and 
proteins were the sum of 1000 shots on the same sample spot, external calibration was used. 
Data processing was executed with Flex Analysis software packages (version: 2.4.). For the 
in-silico digestion Sequence Editor software (Bruker Daltonics) was used with the following 
criteria:  
(i) all cysteines (C) were supposed to be treated with iodoacetamide,  
(ii) monoisotopic masses were allowed and  
(iii) the maximum number of missed cleavage sites was two. 
 
 
 
 
 
 
3.2 Material and methods for experiments of the boronate affinity 
chromatography 
The second part consists of the description of the instrumentation and methods of the 
optimization and application of boronate affinity enrichment of the glycated peptides.  
 
3.2.1 Materials 
Acetonitrile (ACN), methanol (both gradient grade), human serum albumin (HSA, 97-99%), 
ribonuclease A (RNase, from bovine pancrease, >90 %), trifluoroacetic acid (TFA, ≥99%), α-
cyano-4-hydroxycinnamic acid (CHCA, ≥99 %), 2,5-dihydroxybenzoic acid (DHB, ≥99%), 
sinapinic acid (SA, ≥99%), D/L-dithiothreitol (DTT, >99 %), taurine (≥98 %), iodoacetamide 
(≥98 %), 2-mercaptoethanol (≥98 %), ammonium bicarbonate (>99 %) were purchased from 
Sigma-Aldrich (Budapest, Hungary). D-glucose monohydrate (puriss), D-sorbitol (puriss) 
urea, sodium hydroxide (analytical grade), magnesium sulfate (analytical grade), ammonium 
hydroxide (25 %, analytical grade), toluene (>99 %) and tetrahydrofuran (>99.8 %) were from 
Reanal Finechemical Co. (Budapest, Hungary). Formic acid (98-100%) was bought from 
Scharlau Chemie S.A. (Barcelona, Spain). Peptide calibration standard (consisting of 
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bradykinin, angiotensin II, angiotensin I, substance P, renin substrate, ACTH clip (1-17), 
ACTH clip (18-39) and somatostatin) and protein calibration standard (consisting of 
trypsinogen, protein A, BSA, BSA-dimer) were obtained from Bruker Daltonics (Bremen, 
Germany). Trypsin (sequencing grade, modified) was provided by Promega Corporation 
(Madison WI, USA). Bidistilled water was prepared in our laboratory. 
 
 
3.2.2 Instrumentation 
An AUTOLAB12 electrochemical workstation controlled with GPES software 
(version 4.9.009 for Windows, Eco Chemie, Utrecht, Netherlands) served as an amperometric 
measurement instrument. A homemade flow injection analysis (FIA) manifold [87] was used 
for amperometric glucose analysis of eluted samples. A wall-jet-type detector cell containing 
working, counter, and reference electrodes was applied in the manifold (Figure 8). A platinum 
wire of 1 mm diameter served as counter electrode, as did a silver wire for semireference. A 
copper microdisk working electrode of 30 µm diameter and 0.1 M sodium hydroxide carrier 
solution was employed in the FIA glucose measurements. 
For analyzing glucose samples obtained with sorbitol elution from the boronate affinity tips, 
amperometric glucose biosensor was used. The reason why a selective biosensor needed to be 
employed is that sorbitol also reacts to copper electrodes in basic media; therefore, its 
oxidation current would have interfered in the case of FIA measurements. The glucose 
electrode was prepared in our laboratory by immobilizing glucose oxidase enzyme on a 
platinum disk surface (diameter) of 1 mm [88]. The measurements with the biosensor were 
carried out in intensively stirred phosphate buffer (pH 7.4). Buffer (5 ml) was pipetted into a 
small beaker used as measurement cell, small doses of calibrating standards or samples were 
added, and the amperometric current at 0.65 V (vs. Ag/AgCl reference) was taken for 
calibration or concentration evaluation.  
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Figure 8: The walljet type detector cell arrangement [88] 
 
 
For the presentation of the MALDI and HPLC instruments see section 3.1.1. 
The µ-LC device consisted of an Ultimate µ-HPLC pump with column oven, a Switchos µ-
column-switching device with loading pump and two 10-port valves, and a FAMOS µ-
autosampler (LC Packings, Amsterdam, Netherlands). Hyphenation to the mass spectrometer 
was carried out by a nanoflow electrospray ionization source from Proxeon (Odense, 
Denmark) with Pico Tips from New Objective (FS360-20-10, Woburn, MA, USA). Mass 
spectrometric data were obtained on the linear ion trap LTQ mass spectrometer from Thermo 
Fisher Scientific (Waltham, MA, USA). A database search was carried out with 
BioworksBrowser 3.3.1 SP1 (Thermo Fisher Scientific) and Sequest against the Swiss–Prot 
database. 
 
3.2.3 In-vitro glycation of RNase A and HSA 
Glycation and the purification after glycation of HSA and RNase A were implemented 
the same way as described in section 3.1.3. above [81]. Solutions of RNase A were incubated 
for 14 days, whereas solutions of HSA were incubated for 12 and 28 days. Incubations were 
carried out under aseptic conditions at 37 °C.  
In-vitro glycated HSA can be glycated in-vitro range from minimal levels (<10 mol 
modification sites per mol protein) to high levels (30-40 mol modification sites per mol 
protein). Highly glycated HSA is the better model to investigate the possible glycation sites of 
the HSA for patients suffering from type 2 diabetes mellitus [67]. 
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3.2.4 Optimization of composition of binding buffer and circumstances of elution 
using amperometric method 
In the first experiment, an ammonium chloride solution at a concentration of 250 mM 
was prepared and the pH values of this solution were adjusted by adding ammonia to obtain 
binding buffers with pH values of 7.4, 7.8, 8.2, 8.6, 9.0, and 9.4. Each solution contained 50 
mM magnesium sulphate. After rehydration boronate affinity tips were equilibrated with the 
binding buffers mentioned above, 0.01 mol D-glucose was dissolved in 10 ml of binding 
buffer and the solution was aspirated through the affinity gel. This was followed by a washing 
step using binding buffer to eliminate the nonbound glucose. Finally, the elution of the bound 
D-glucose was carried out using 200 µl of formic acid solution with a pH value of 2.0. In the 
next experiment, the pH was kept at a constant level and the concentration of the ammonium 
chloride was changed from 50 to 300 mM. Then 0.01 mol D-glucose was again dissolved in 
solution and aspirated through the gel slab of the tips. Elution of the bound glucose was 
implemented using 200 µl of formic acid solution at pH 2.0. 
From these experiments, the binding buffer in which the tip possessed the highest 
binding capacity toward glucose was chosen and the elution was investigated using formic 
acid from pH 2.0 to pH 5.0. Additional experiments for the optimization of the elution include 
the use of sorbitol at higher concentrations to remove D-glucose from the boronate affinity 
tips in the range from 0.1 to 1.6 M. It is important to mention that the presence of sorbitol had 
no disturbing effect on the amperometric measurement carried out with the glucose biosensor. 
Water from the eluates was evaporated under vacuum, and the remaining solid was taken up 
in 100 µl of double distilled water and analyzed by means of the amperometric method using 
either a wall-jet-type detector or a biosensor.  
 
3.2.5 Isolation and purification of HSA from serum samples obtained from 
patients suffering from type 2 diabetes mellitus and from healthy volunteers. 
Human sera taken from diabetic patients and healthy volunteers were diluted 20 times 
with double distilled water, and then 2 ml of this solution was centrifuged through a Centricon 
Ultracel YM-50 centrifugal filter tube (Millipore) at 5000g for 20 min (cutoff: 50,000 Da). 
This centrifugation ensured the removal of serum constituents with masses less than 50,000 
Da; this step helped to prolong the lifetime of the RP-HPLC column. Proteins remaining on 
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the filter were further diluted with double distilled water 20 times, and the HSA was separated 
on a Kovasil MS-C18 non-porous column (Zeochem AG, Uetikon, Switzerland).  
Eluent A consisted of 5% (v/v) ACN in water and 0.1% TFA, and eluent B consisted of 95% 
(v/v) ACN and 0.1% TFA. The gradient profile was: 0–20 min, 0% B→60% B; 20–25 min, 
60% B→100% B. The flow rate was 0.7 ml × min-1. Chromatograms were acquired at 214 
nm. Fractions collected from sera were evaporated to dryness before digestion.  
 
3.2.6 Tryptic digestion of glycated HSA and RNase A  
The tryptic digestion of 1mg HSA, 1mg RNase A (Sigma-Aldrich) was carried out 
similarly to the way described in section 3.1.5 above. In the case of HSA isolated from sera, 
approximately 300 µg of proteins was in-solution digested using the protocol described 
above.  
 
3.2.7 Enrichment of glycated peptides using boronate affinity tips  
Pipette tips containing 5 µl of gel of immobilized m-aminophenylboronic acid with a 
total volume of 200 µl (PhyTip 1000+ columns, PhyNexus, San Jose, CA, USA) were used 
for the enrichment of the glycated peptides. After rehydration, the tips were equilibrated with 
binding buffers. The digest of 100 µg of protein (for each protein) was dissolved in the 
binding buffer, and the solution was aspirated through the affinity gel. Then the tips were 
washed with 1 ml of binding buffer to remove unselectively bound peptides. This was 
followed by an additional washing step with double distilled water to eliminate the trace of 
salts presented in the buffer if the elution was carried out using formic acid. Glycated peptides 
were eluted with 4x 50 µl of formic acid solution at pH 2.0. Elution of the bound glycated 
peptides has also been accomplished using sorbitol at higher concentrations. In the case of 
elution with sorbitol, prior to MALDI measurement the glycated peptides needed to be 
desalted using different sorbents (see 3.2.8). 
 
3.2.8 Desalting of glycated peptides eluted from tips with sorbitol 
For the desalting of glycated peptides eluted from boronate affinity tips, three different 
solid phase extraction (SPE) sorbents were compared. Here 5 mg from fullerene-derivatized 
silica particles made from a silica with a pore diameter of 30 nm (C60(30) silica) and 5 mg 
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octadecyl silica (C18 silica) was packed in SPE cartridges (Alltech Extract–Clean SPE 1.5 ml 
reservoir, Alltech Associates, Deer-field, IL, USA). The activation and equilibration method 
were the same as described in section 3.1.6. Elution of the bound peptides was implemented 
with 300 µl of 80% ACN and 0.1% TFA in water. The eluate was evaporated to dryness, and 
the peptides were taken up in 5 µl of 0.1% TFA in double distilled water. Then 1 µl of this 
solution was deposited on a stainless steel target mixed with 1 µl of matrix. 
The desalting of glycated peptides was also carried out using the commercially available 
ZipTip (Millipore). For the activation, equilibration, and elution, the same conditions were 
used as for the C60(30) and C18 silica materials. In the case of ZipTip, the eluate was 
deposited directly onto a stainless steel target in 1 µl of 80% ACN and 0.1% TFA in water 
and then mixed with 1 µl of matrices and analyzed. 
 
3.2.9 Preparation of different MALDI matrices 
Two different matrices were compared for the ionization of glycated peptides. DHB 
was prepared in 20% (v/v) ACN and 0.1% TFA in water at a concentration of 25 mg×ml-1. A 
mixed matrix consisting of DHB and CHCA was also recommended for the MALDI–TOF 
analysis of glycated peptides [28]. CHCA (2 mg) was dissolved in 100 µl of 70% ACN and 
5% formic acid. In addition, 2 mg of DHB was dissolved in 100 µl of 70% ACN and 0.1% 
TFA, and these two solutions were mixed in a 1:1 ratio. 
For the measurement of glycated proteins, a saturated SA matrix was prepared in 50% (v/v) 
ACN and 0.1% TFA in water. 
 
3.2.10 Conditions of electrochemical measurements  
When using a wall-jet-type detector cell in flow injection analysis (FIA) mode, the 
electrochemical measurements were made in 100 mM sodium hydroxide solutions at a flow 
rate of 2 ml × min-1. In the case of using an enzyme sensor, the glucose measurement was 
carried out in a 10 ml electrochemical cell applying a three electrode cell ensemble. Then 5 ml 
of isotonic PBS buffer (pH 7.4) was pipetted into the cell. During the measurement, 0.65 V of 
working potential was used while the electrolyte solution was stirred continually. 
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3.2.11 MALDI–TOF/MS conditions 
For the description of the MALDI measurements of proteins and peptides see section 
3.1.11 above. 
 
3.2.12 µLC–MS conditions 
A poly(p-methylstyrene-co-1,2-bis(p-vinylphenyl)ethane)-based monolityc stationary 
phase [89] was used for the separation of the peptides of digests. The separation was 
performed under reversed phase conditions with eluent A (0.1% formic acid in water) and 
eluent B (0.1% formic acid in 30% ACN) at a flow rate of 1 µl × min-1 and 40 °C. A linear 
gradient (0–50 min: 0% B→60% B) was used. Mass spectrometric measurements were 
performed in positive ESI mode. The source voltage was adjusted at 1.4 kV, the capillary 
temperature was kept at 220 °C, the capillary voltage was at 37 V, and the tube lens was set at 
94 V. When analyzing the results with Sequest, the following parameters were adjusted: 
I. carbamidomethylation on cysteine (C) as fixed modification 
II. 144 and 162 (fragments of glucose) variable modifications at lysine (K) and arginine 
(R) 
III. three possible missed cleavage sites were allowed. 
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4. Results and discussion 
 
4.1 Results of the solid phase (SPE) experiments 
The first part of the results and discussion involves the achievement of the solid phase 
extraction, recovery of the solid phases and fractionation of the glycated peptides. 
 
4.1.1 Comparison of the phases – recovery study (quantitative evaluation) 
 
To identify the binding capacity of C30 and C60(30) the particles were incubated with 
a solution of Leu-enkephalin at different concentrations under vigorous shaking at 20°C. Then 
particles were centrifuged and the supernatants were analyzed. The concentrations of the 
supernatants represent equilibrium values with the adsorbed Leu-enkephalin. A calibration 
curve was plotted by the measurement of standard solutions of Leu-enkephalin (R2 = 0.9899) 
at 232 nm employing UV–Vis spectrophotometry. The adsorption isotherms can be depicted 
plotting the concentrations of supernatants (Cequ, expressed in µg × mL-1) against the adsorbed 
amount (mads, expressed in µg) (Figure 7/A). Data points fit the theoretical adsorption model 
of Langmuir with an excellent linear regression (R2 = 0.994 for C60(30) and C30-silica, both) 
when plotting Cequ against Cequ/mads (Figure 7/B) [23]. The binding capacities were calculated 
from the reciprocal slope of the lines [86]. 
 
 
Figure 7. (A) Adsorption isotherms of Leu-enkephalin measured on C30-silica and 
C60(30) at 25°C. (B) The linearised forms of the isotherms. The reciprocal slope of the lines 
gives the binding capacity of the phases in saturation. 
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To characterise the sorption behaviour of the phases a mixture of three peptides 
([Arg8]-vasopressin, Leu-enkephalin, angiotensin I) was loaded onto the cartridge in three 
different concentrations (10, 30 and 50 µg). Peptides presented in the eluate and breakthrough 
were measured. Table 1 shows data on the recoveries and the amount of peptides lost during 
the whole procedure that enabled the quantitative determination of the analytes. 
Fullerene(C60)-silica prepared from 30 nm pore size silica material, C60(30) has proven to be 
the best (Table 2), in so far as no peptides could be detected from the breakthrough, by 10 µg 
loaded from each peptides. For vasopressin 66.2% of recovery was received indicating that 
33.8% of the loaded peptide was lost through the sample preparation. The same conclusion 
can be drawn for each phase. For instance, in the case of fullerene(C60)-silica made up from 
10 nm pore-size silica gel (C60(10)) the recovery of vasopressin was found to be 23.7%. In 
the breakthrough, 40.7% of 10 µg could be measured (64.4% of the total amount). C60(30) 
provided 94.7% recovery for angiotensin I, and 86.3% for Leu-enkephalin.  
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10µg
µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E
[Arg8]-vasopressin 1.7 17 1 5.6 56 8 -27 4.4 44 8 2.8 28 2 -28 2.4 24 9 4.1 41 6 -35 6.6 66 8 n.d. - - -34 5.5 55 8 1.2 12 2 -33
Leu-enkephalin 2.6 26 7 7.6 76 10 +2 7.1 71 6 3.0 30 2 +1 6.7 67 2 5.4 54 10 -21 9.5 95 8 n.d. - - -5 8.8 88 7 3.0 30 5 +18
angiotensin I. 2.5 25 2 3.9 39 3 -36 8.1 81 4 1.5 15 10 -4 4.6 46 2 4.5 45 3 -9 8.6 86 7 n.d. - - -14 7.9 79 1 0.6 6 8 -15
30µg
µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E
[Arg8]-vasopressin 7.3 24 2 9.4 31 3 -45 12.0 40 2 7.1 24 5 -36 2.9 10 4 16.5 55 10 -35 13.0 43 6 5.4 18 10 -39 7.9 26 9 9.4 31 8 -43
Leu-enkephalin 13.2 44 10 13.6 45 9 -11 21.2 71 1 10.1 34 10 +5 10.0 33 4 23.8 79 7 +12 15.6 52 10 10.2 34 2 -14 16.0 53 7 16.3 54 5 +7
angiotensin I. 17.1 57 10 6.1 20 4 -23 24.6 82 10 2.9 10 6 -8 5.4 18 1 24.2 81 9 -1 20.1 67 3 4.0 13 2 -20 13.2 44 3 9.6 32 10 -24
50µg
µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E µg %
RSD
% µg %
RSD
% E
[Arg8]-vasopressin 9.7 19 1 33.1 66 8 -15 13.5 27 5 14.4 29 9 -44 2.8 6 4 31.6 63 8 -31 16.7 33 10 17.9 36 10 -31 8.1 16 7 27.9 56 9 -28
Leu-enkephalin 18.2 36 1 24.8 50 3 -14 32.2 64 2 13.2 26 9 -10 12.2 24 4 40.3 81 10 +5 15.5 31 7 25.8 52 2 -17 18.5 37 3 23.3 47 1 -16
angiotensin I. 24.0 48 8 35.5 71 3 +19 30.7 61 1 9.4 19 9 -20 8.1 16 3 40.2 80 2 -4 26.9 54 5 14.6 29 10 -17 16.2 32 3 22.0 44 6 -24
eluate BTeluate BT eluate BTeluate BT eluate BT
eluate BTeluate BT eluate BTeluate BT eluate BT
BT
C60(100)
eluate BT eluate BT eluate BT eluate BT eluate
C18 C30 C60(10) C60(30)
 
 
 
Table 1. Recovery study using different SPE materials 
Each solution was three times loaded and measured on each phase. BT, Breakthrough; E (%), Error; n.d., not detected. 
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Phases Pore size (nm) 
Specific 
surface area 
(m2×g-1) 
Pore 
volume 
(mL×g-1) 
Surface 
coverage 
(µmol×m-2) 
     
Kovasil 110 C18 7.1 200 0.48 3.76 
Kovasil 160 C30 9.6 155 0.49 3.79 
Kovasil 100 C60 0 265 0 0.88 
ProntoSil 300 C60 13 114 0.3 2.91 
GromSIL 1000 C60 n.m. 32 n.m 2.27 
 
Table 2. Properties of the investigated phases 
 
Among fullerene-derivatised silica materials the recoveries of all peptides are the lowest for 
C60(10), due to the obstructed pores and consequently the lack of pore volumes. It is worth 
noting that the recoveries for C30-coated particles and for C60(100) particles are similar, 
despite the fact that the surface area of C30-silica is approximately five times higher than the 
surface area of fullerene C60(100)-silica. The reason for that is the different selectivity of the 
C30 moieties and the spherical C60 attached to the silica. In contrast to C60 phases recoveries 
decrease only slightly on C30-silica, witch is explained by the different sorption behaviour of 
the two packings: the binding capacity of C30 phase surpasses the binding capacity of C60 
phase (Figure 7/A). The binding capacity of C60(30) is 31.5 mg×g-1, which confirms a 
previously published result obtained for phosphopeptides (33.6 mg×g-1) [42]. This value is 
153.9 mg×g-1 for C30-silica showing a five times higher binding capacity.  
 
Table 1 shows that for all materials recoveries dramatically decrease if the cartridges are 
overloaded with peptides (50 µg from each). Considering the results provided by this recovery 
study a considerable attention must be paid to the hydrophobicity of the authentic peptides 
used in this study in comparison with the hydrophobic properties of the investigated SPE 
materials. Overall, for the most hydrophilic [Arg8]-vasopressin among all the investigated 
phases the best recoveries could be achieved using C60(30) as SPE material. This supports the 
observation that the presence of fullerene attached to the silica support provides material with 
excellent hydrophobic properties, thus enabling the binding of very hydrophilic peptides. 
Angiotensin I, the most hydrophobic peptide could be recovered in the highest amount from 
the phases derivatised with long alkyl moieties (like C18 and C30), nearly independent of the 
loaded amount. In the case of C60-silicas, it is noteworthy, that at 10 µg from each peptide 
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loaded onto the cartridges, Leu-enkephalin had better recovery than the more hydrophobic 
angiotensin I. When overloading C60-silicas with 30 and 50 µg peptides, respectively, 
angiotensin I possessed better recoveries than Leu-enkephalin. To explain the reason behind 
this phenomenon it can be assumed that at 10 µg of the peptides (when the phases are not 
overloaded) the accessibilities of the two-time shorter Leu-enkephalin molecules to the 
spherical fullerene molecules are not as hindered as angiotensin I.  
 
 
4.1.2 Comparison of the phases based on the sequence coverage of HSA and 
fibrinogen digests received after stepwise SPE fractionation  
Three MALDI matrices were tested for sequence coverage of an HSA digest. For 
comparison of the experimentally measured and in-silico generated masses (allowing 50 ppm 
mass tolerance) Böddi et al. developed a software that enables the comparison of two series of 
masses within a mass tolerance of 50–150 ppm if the total sequence of the protein is known, it 
is also possible to calculate the sequence coverage of the protein from data provided by the 
PMF (www.fraki.lgx.hu). 
Matrices prepared as described in Section 3.1.10 were mixed with 20 pmol HSA digest on a 
stainless steel target and analysed. Allowing 50 ppm mass tolerance 38.6% of sequence 
coverage was calculated, if CHCA was used. In case of adjusting 150 ppm error for mass 
tolerance the sequence coverage only irrelevantly increased (42%), indicating that the 
MALDI measurement was accomplished accurately. 
THAP, a matrix being frequently used for the ionisation of glycopeptides [26] was also tried. 
For the rough crystals of THAP, high laser energy is required, which results in higher mass 
errors, e.g.: at 50 ppm mass tolerance the sequence coverage of HSA (20 pmol) was only 
47%, however, it increased to 68% when 150 ppm tolerance was permitted. 
For the digests of HSA and fibrinogen, DHB has proven to be the optimal matrix because of 
the fine, needle-like crystals that can be excited by a low energy of a laser beam. This offers 
good resolution and reliable measurements with regard to mass accuracy: when 50 ppm of the 
tolerance was allowed, 69% of the sequence coverage was achieved, by increasing the 
tolerance to 150 ppm, the sequence coverage was found to be 71.5%. Due to the favourable 
properties of DHB, this matrix was further used for the MALDI analysis of both unmodified 
and glycated protein digests. 
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Digests of HSA and fibrinogen were fractionated on each SPE material. Results are 
reported in Table 3. In the case of fractionation of 20 pmol HSA digest, C18- and C30-silicas 
provide better coverages than the C60-silica materials in so far as 80.5% of the amino acids of 
HSA was identified after separating the peptides on C18-silica particles. This was found to be 
80.7% on C30-silica, respectively. C60(30) enabled the identification of 70.8% of the amino 
acids of HSA. 
Fibrinogen is a glycoprotein with a molecular weight of about 340 kDa. The molecules are 
comprised by two sets of disulphide-bridged Aα-, Bβ- and c-chains and play an important role 
in blood clotting [90]. 
 
 
 HSA Fibrinogen total coverage of fibrinogen 
  Aα Bß c  
digest 71.5% 56.2% 62.3% 30.5% 50.4% 
C18 80.5% 51.7% 44.0% 24.3% 41.5% 
C30 80.7% 62.4% 63.6% 37.1% 55.6% 
C60 (10 nm) 64.7% 45.8% 31. 6% 27.6% 36.2% 
C60 (30 nm) 70.8% 59.5% 63.1% 64.9% 62.2% 
C60 (100 nm) 56.4% 50.6% 51.5% 24.5% 43.4% 
 
Table 3. Sequence coverages achieved on the phases by fractionation of 20 pmol HSA and 
fibrinogen digest 
 
By the fractionation of the digest on C18-silica and C60(100) materials provided very 
similar results concerning the total coverage of fibrinogen (41.5% vs. 43.4%), however for 
Bβ-chain a slightly better result was achieved on C60(100). 
While for both C30-silica and C60(30), the sequence coverage results were the same for Aα- 
and Bβ-chains an outstanding value for c-chain (64.9%) was achieved on C60(30), which 
raised the total coverage up to 62.2%. 
As concluded, peptides of a tryptic digest comprising mainly hydrophilic amino acids are 
capable of binding stronger on a C60 derivatised silica material. The length of the peptide 
does play an important role because those peptides consisting of more amino acid residues 
have better access to the alkyl moieties – and therefore they generated stronger interactions – 
than to the spherical C60 molecules. Due to highest percentage of the aromatic amino acids in 
the c-chain of fibrinogen (11.26% of the total amino acid residues) the π–π interactions 
between the peptides and the fullerene play more important role than in the case of Aα- and 
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Bβ-chains (6.37 and 7.74% of the total amino acid residues). The π–π interactions must be 
responsible for increasing the sequence coverage of c-chain when the peptides are eluted from 
C60(30). Based on the results reported in Sections 4.1.1 and 4.1.2 C30 silica and C60(30) (the 
best two) SPE materials were used for the analyses of glycated HSA and fibrinogen tryptic 
digests. 
 
 
4.1.3 Identification of the possible glycation sites of HSA and fibrinogen after 
fractionation –comparison of the results provided by SPE experiments to 
boronate affinity chromatography  
In hyperglycaemia HSA, the most abundant protein in serum can be non-
enzymatically glycated via its basic amino acid residues. Glycated HSA is an excellent 
marker in diabetes and it can be used as a mid-term index of glycaemic control 
(approximately 20 days half-life). The role of glycated HSA in the identification of different 
stages of diabetes is clarified. The possible glycation sites of HSA (Figure 9) have been 
extensively studied with a number of methods including LC-MS and LC/off-line MALDI [50, 
53, 54, 55, 67]. 
The applied SPE/off-line MALDI methods using novel phases made a comparison of the 
phases possible, using methods published for glycated HSA.  
 
 
Figure 9: Lysines (K) and arginines (R) in HSA, there are the possible glycation sites of the 
human serum albumin [67]. 
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Fibrinogen may significantly contribute to an increased risk of cardiovascular disease 
in patients with diabetes both in that they generally have elevated fibrinogen levels and that 
fibrinogen undergoes non-enzymatic glycation in the presence of uncontrolled blood glucose 
levels in the diabetic subjects. This glycation can alter the structure and function of the 
fibrinogen; therefore it is important to gain information about the possible glycated sites of 
this protein. Moreover, the analysis of fibrinogen, protein with a higher molecular weight, 
(glycated sites never studied before) emphasizes the selectivity differences between the 
phases. 
Although several advanced glycated end products (AGE) have been described, in this work 
the identification of Amadori products (glucose molecules react with free amine groups 
forming glycosylamine residues through a reversible process, and later the glycosylamine can 
undergo an Amadori rearrangement to form a stable fructosamine residue (Figure 10)) and 
fructosil-lysine were the object of the investigation. 
 
 
 
 
 
 
 
Figure 10: Structure of the Amadori Compounds formed on the lysine of the protein 
[67] 
 
 
Figure 11 shows the workflow elaborated for the investigation of the glycated residues.  
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Figure 11: The elaborated workflow for the investigation of glycated peptides with SPE 
 
Condensation of a glucose unit on an amine group causes 162.05 Da mass increase of 
a tryptic peptide if only one residue in the peptide is glycated. The masses of in-silico 
digestion were enhanced with 162.05 Da and compared to the measured masses of the 
glycated fractions with a mass tolerance of 100 ppm [26]. 
 
The effects of non-enzymatic glycation on the molecular weight on HSA and fibrinogen are 
shown in Figure 12. In the case of HSA nearly 5 kDa mass shift was measured similarly to 
Brancia et al. [92]. Calculating on the basis of this mass shift between non-glycated and 
glycated HSA, on the average 31 glucose units were found to be condensed on an HSA 
molecule. Boronate affinity tips were used for the selective enrichment of fibrinogen from a 
saline solution, to gain a better determination with MALDI despite the poor solubility and 
high molecular weight of this protein. The bound protein was directly eluted onto a target 
with formic acid. The mass received (Figure 12/C) is consistent with that described in the 
literature [95]. In contrast to HSA, the mass of fibrinogen is reduced during the glycation 
(Figure 12/D). This can be ascribed to the short half-life of the fibrinogen (4 days) [94]. 
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Figure 12: Comparison of unglycated (A) with glycated (B) HSA and unglycated (C) with 
glycated (D) fibrinogen. Each spectrum was monitored in linear mode and is a sum of 1000 
shots. The applied matrix was SA. 
 
 
Figures 13 and 14 demonstrate the influence of fractionation on the identification of 
glycated peptides. Figure 13/A is a part of the spectrum of the glycated HSA digest ranging 
between 1500 and 2000 Da. This complex mixture of peptides was loaded onto C60(30) 
particles and the peptides were stepwise eluted with an increasing amount of ACN. Figure 
13/B is a spectrum showing peptides eluted with 20% of ACN. A peptide at 1628.85 Da 
appeared in the fraction at high intensity. The very intense signal that is suppressed in the 
unfractionated digest made it possible to acquire the appropriate PSD spectrum (Figure 13/C). 
The presence of the two distinctive peaks generated by neutral losses supplied further 
evidence for glycation at 1508.8 and 1466.7 Da. At the C-terminus of this peptide an arginine 
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is localised resulting in y-type ions in larger population. This peptide modified with a glucose 
unit at K475 has a sequence of VTKCCTESLVNR at the position of 473–484 of the HSA.  
 
 
 
 
Figure 13: SPE of a glycated HSA digest on C60(30). (A) Unfractionated digest of HSA, (B) 
peptides released when 20% of ACN was employed as an eluent. Peptides assigned with 
asterisks are glycated. (C) PSD spectrum of a single glycated peptide at m/z 1628.85. For the 
parent ion 1000 shots were collected. The peak at m/z 1466.71 was formed by a neutral loss 
of dehydrated glucose (–162 Da), the other distinctive peak at m/z 1508.81 is a result of a 
neutral loss of a fragment of glucose (–120 Da). Spectra A and B were collected in reflectron 
mode. For each spectrum 1000 shots were acquired. The assigned y-ions in the low-mass 
range provide structural evidence for the sequence. The matrix applied was 2,5-dihydroxy 
benzoic acid. The presence of y-type ions refers to the arginine-terminated peptide. 
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Figure 14: SPE of a glycated fibrinogen digest on C30-silica. (A) Unfractionated digest of 
fibrinogen, (B) peptides released when 10% of ACN was employed as an eluent. Peptides 
marked with asterisks are glycated. (C) PSD spectrum of a double glycated peptide of the c-
chain at m/z 1672.88. For the parent ion 1000 shots were collected. The peak at m/z 1510.88 
was formed by a neutral loss of dehydrated glucose (–162 Da), the other distinctive peak at 
m/z 1553.27 is a result of a neutral loss of a fragment of glucose (–120 Da). The presence of 
y-type ions in the low-mass range of the spectrum corroborates the identified sequence. 
Spectra A and B were collected in reflectron mode. For each spectrum 1000 shots were 
acquired. The applied matrix was 2,5-dihydroxy benzoic acid. 
 
 
Although the spectrum of a glycated fibrinogen digest fraction from C30-silica seems 
to be more complex, between 1600 and 1700 Da two additional glycated peptides can be 
successfully detected. The peptide at 1672.8 Da is further studied by its MS/MS spectrum. 
The corresponding peaks – indicating the neutral losses of the dehydrated glucose (–162 Da) 
and its fragment (–120 Da) appear at 1510.8 and 1553.3 Da, respectively (Figure 14). 
According to the MS/MS spectrum of this modified peptide a double glycated peptide of the 
c-chain with the corresponding sequence of KTTMKIIPFNR at the position of 407–417 has 
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been identified. Modifications with two glucose units are at K407 and K411, respectively. 
The sequence of this peptide is verified by those y-type fragments in the low-mass range 
(Figure 14/C).  
 
Boronate affinity chromatography is a useful tool for the enrichment of glycated 
and/or glycosilated proteins and peptides [69]. The glycated peptides captured using boronate 
affinity PhyTip 20 pmol glycated HSA digest (Figure 15/A) and from 20 pmol digest glycated 
fibrinogen (Figure 15/B) are shown. As shown in Figure 15/A, the most prominent, assigned 
peaks belong to 11 single glycated and 3 double glycated peptides. However, a considerably 
higher number of modified peptides has been monitored (for details see Tables 4, 5, 6 and 7). 
For instance, the most abundant peak appearing at m/z 1760.40 is a double glycated peptide 
where the possible glycated sites are K199 or K205 or R209. In addition, K276, K525 and 
K545 are considered to be privileged glycation sites, in agreement with the fractional solvent 
accessible surface values calculated by molecular modelling [95]. K276 is a modified residue 
of a double modified peptide detected at m/z 1870.42, while K525 and K545 were monitored 
from a single and a double glycated peptide measured in order at m/z 1290.48 and 2464.75. 
 
Figure 15/B shows glycated peptides captured by boronate affinity tips from 20 pmol 
digest of glycated fibrinogen. Although Aα-chain is the largest part of this glycoprotein and 
from the minor peaks several possible glycated sites have been calculated, the most intensive 
peaks of this spectrum can, as a rule, be assigned to the double and single glycated peptides of 
Bβ- and c-chains of fibrinogen. The peak appearing at m/z 1672.82 is a double glycated 
peptide of c-chain (KTTMKIIPFNR) having a location of [407–417] and probably modified 
at K407 and K411. K411 as a possible glycated site is further confirmed by the presence of a 
single glycated peak of c-chain at m/z 1382.72 (TTMKIIPFNR) at the location of [408–417]. 
Evidence for the modification of K411 is provided by the corresponding PSD spectrum. 
Taking into account the number and the intensity of the modified peptides of Bβ-chain and c-
chain of this protein, Bβ- and c-chains seem to be most accessible for non-enzymatic 
glycation process.  
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Figure 15: Boronate affinity capture of glycated peptides. (A) Glycated peptides after 
selective enrichment from 20 pmol glycated HSA digest. (B) Glycated peptides after selective 
enrichment from 20 pmol glycated fibrinogen digest. Spectra were monitored in reflectron 
mode. Each spectrum is a sum of 1000 shots. The matrix applied was 2,5-dihydroxy benzoic 
acid. 
 
 
Table 4 below summarises all possible single glycated sites of HSA obtained on C30-
silica and C60(30) and compared with the unfractionated digest and boronate affinity. Sixty-
nine possible glycated sites (arginine and lysine) were successfully identified. Fifty-nine of 
these have been described in the literature [67, 81, 92, 93]. Data obtained from SPE 
experiments made it possible to recognise glycation that could not be detected from the digest. 
Peptides with two modified sites were also determined and no additional glycation were 
found. As long as from the digest 6 double modified peptides were only measured, 11 
peptides with 2 modified residues were bound both on C30-silica and C60(30). Using 
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boronate affinity 14 double glycated peptides have been identified (these data are not reported 
in detail). Ten unknown modification sites have been identified. 
 
 
  
D C30 C60 B 
[  1- 10] K4 or R10    + 
[  5- 12] R10 or K12 +    
[ 11- 20] K12 or K20 + + +  
[ 13- 20] K20   +  
[ 65- 81] K73 or R81   + + 
[ 82- 93] K93  +   
[ 82- 98] K93 or R98 + +   
[ 94- 98] R98    + 
[ 99-106] K106  +   
[107-114] R114  + +  
[137-144] K137 or R144 + + + + 
[137-145] K137 or R144 or R145  +   
[138-144] R144   +  
[145-160] R145 or K159 or R160 +   + 
[146-160] K159 or R160    + 
[160-174] R160 or K162 or K174    + 
[161-174] K162 or K174 + + +  
[175-186] K181 or R186 + + +  
[187-195] K190 or K195  + +  
[187-197] K190 or K195 or R197   +  
[191-197] K195 or R197 +  + + 
[196-205] K199 or K205 + +   
[198-205] K199 or K205 + + + + 
[198-209] K199 or K205 or R209   + + 
[200-209] K205 or R209 + + + + 
[200-212] K205 or R209 or K212    + 
[206-218] R209 or K212 or R218  + +  
[210-218] K212 or R218 + + + + 
[210-222] K212 or R218 or R222    + 
[213-222] R218 or R222   +  
[219-225] R222 or K225  + +  
[219-233] K225 or K233 +   + 
[226-233] K233 +  +  
[226-240] K233 or K240 +  +  
  
D C30 C60 B 
[258-274] K262 or K274 + + + + 
[263-276] K274 or K276 + + +  
[275-286] K276 or K281 or K286 + + + + 
[277-286] K281 or K286    + 
[314-323] K317 or K323 + + +  
[318-336] K323 or R336 +    
[318-337] R336 or R337    + 
[324-336] R336 +    
[338-348] R348  + + + 
[349-359] K351 or K359 + + + +
[352-359] K359  +   
[403-413] R410 or K413   + +  
[403-410] R410 + + +  
[403-414] R410 or K413 or K414  + +  
[411-428] K413 or K414 or R428    + 
[414-428] K414 or R428 + + + + 
[415-436] K432 or K436    + 
[429-439] K432 or K436 or K439 +    
[433-444] K436 or K439 or K444  +   
[437-444] K439 or K444  +   
[437-445] K439 or K444 or R445   +  
[467-484] R472 or K475 or R484 + +  + 
[473-484] K475 or R484    + 
[501-521] K519 or R521 +    
[520-525] R521 or K524 or K525  +    
[525-534] K525 or K534 + + + + 
[535-541] K536 or K538 or K541 +   + 
[539-557] K541 or K545 or K557    + 
[558-564] K560 or K564 +  +  
[558-573] K560 or K564 or K573 +    
[561-574] K564 or K573 or K574  + +  
[565-574] K573 or K574  + +  
[574-585] K574 + + + + 
 
Table 4. Monitored glycated residues located on HSA  
The positions of detected peptides are given in brackets. D, digest; C30, C30-silica, C60, 
C60(30); B, boronate phase. Bold type indicates the ten unknown modification sites. 
 
 
Table 5 below demonstrates the modified residues of fibrinogen. In the sequence of Aα-
chain 72 modifications were found but from the digest only 41 of these sites were identified. 
Using C30-silica 67, by means of C60(30) 63 glycated residues could be identified in SPE 
experiments. Boronate affinity allows identifying only 15 locations. 
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D C30 C60 B 
[  6- 35] R35   +  
[ 36- 42] R38 or R42  + +  
[ 36- 48] R38 or R42 or K48    +  
[ 39- 48] K48 + + +  
[ 39- 63] R42 or K48 or K63   +  
[ 43- 48] K48 + + +  
[ 43- 63] K48 or K63 + + +  
[ 49- 63] K63  + +  
[ 49- 69] K63 or R69  + +  
[ 64- 71] R69 or K71 +    
[ 70- 84] K71 or R84 + + +  
[ 72- 84] R84 + + +  
[ 72- 89] R84 or K87 or K89  +   
[ 85- 97] K87 or K89 or K97 + + + + 
[ 88- 97] K89 or K97  + + + 
[ 90-100] K97 or K100 + + +  
[ 90-114] K97 or K100 or R114  +   
[ 98-114] K100 or R114  +   
[ 98-123] K100 or R114 or R123   +  
[101-114] R114  +   
[101-123] R114 or R123   +  
[115-135] R123 or R129 or R135   +  
[124-129] R129   +  
[130-135] R135   +  
[130-137] R135 or R137  +   
[136-143] R137 or K142 or R143   +  
[138-143] K142 or R143 + + +  
[144-157] K144 or K148 or K157 + +   
[145-160] K148 or K157 or R160  +   
[149-160] K157 or R160    + 
[158-167] K167   +  
[161-167] K167  +   
[161-168] K167 or R168 + + +  
[161-176] K167 or R168 or K176   +  
[168-176] R168 or K176 + +  + 
[168-178] R168 or K176 or R178  +   
[169-178] K176 or R178  +   
[169-181] K176 or R178 or R181  +   
[177-181] R178 or R181   +  
[177-186] R178 or R181 or R186  + +  
[182-190] R186 or R190   +  
[182-195] R186 or R190 or K195  + +  
[187-195] R190 or K195   +  
[191-202] K195 or K202  +   
  
D C30 C60 B 
[196-202] K202  +   
[196-210] K202 or K210 + + +  
[196-216] K202 or K210   +   
[203-216] K210 or R216  + +  
[211-218] R216 or R218  + +  
[211-225] R216 or R218 or K225  + + + 
[226-238] K227 or K238  +   
[226-249] K227 or K238 or K243 or K249 + +   
[244-258] K249 or R258 + + +  
[244-249] K249   +  
[250-258] R258  +   
[250-287] R258 or R263 or R271 or R287  +   
[259-271] R263 or R271  + +  
[272-287] R287   +  
[426-437] R426 or K432 or K437   +  
[427-437] K432 or K437  +   
[427-440] K432 or K437 or K440 + + + + 
[433-440] K437 or K440  + +  
[433-443] K437 or K440 or R443  + +  
[438-443] K440 or R443   +  
[438-446] K440 or R443 or K446  + +  
[444-458] K446 or K448 or R458  + +  
[447-458] K448 or R458  +   
[447-459] K448 or R458 or R459  +   
[460-476] K463 or K467 or K476 + + +  
[464-476] K467 or K476 + + +  
[468-476] K476  + +  
[511-527] R512 or K527 + + +  
[513-527] K527  + +  
[513-547] K527 or R547  +   
[548-558] K558  +   
[548-573] K558 or R573  + +  
[559-575] R573 or K575  +   
[574-581] K575 or K581  +   
[574-591] K575 or K581 or R591 + + +  
[576-591] K581 or R591  + +  
[582-591] R591   +  
[592-599] K599 + + +  
[592-602] K599 or K602    + 
[600-621] K602 or K620 or R621   +  
[603-620] K620 + + +  
[603-621] K620 or R621  +   
[622-630] K625 or R627 or R630 + + +  
[631-644] K639 + + +  
 
Table 5. Monitored glycated residues located on the Aα-chain of fibrinogen 
The positions of detected peptides are given in brackets. D, digest; C30, C30-silica, C60, 
C60(30); B, boronate phase. 
 
 
 
Table 6 below shows the modifications identified from single modified peptides on the Bβ-
chain. Of all the modified sites (59), 25 were found by analysing the digest, while this number 
increased with fractionations on C30-silica (53 sites) and C60(30) (47 sites). Boronate phase 
only recognises 20 residues. 
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D C30 C60 B 
[  4- 11] K11  +   
[  4- 16] K11 or K13 or K16   +  
[ 12- 29] K13 or K16 or K29  +   
[ 45- 51] R47 or K51  + +  
[ 52- 72] K52 or R53 or R60 or R72  +   
[ 53- 77] R53 or R60 or R72 or R74 +    
[ 54- 72] R60 or R72  +   
[ 54- 77] R60 or R72 or R74 or K77   +   
[ 73- 83] R74 or K77 or K83  + + + 
[ 73- 84] R74 or K77 or K83 or K84    + 
[ 78- 84] K83 or K84   +  
[ 84- 88] K84 or R87 or K88   + + 
[125-152] K152  +   
[153-158] K157 or R158 + + + + 
[158-163] R158 or K160 or K163 + + +  
[161-178] K163 or K178  + +  
[164-178] K178  +   
[164-199] K178 or R196 or R199  +   
[197-206] R199 or R206  +   
[197-208] R199 or R206 or K208  + +  
[200-208] R206 or K208 + + +  
[200-206] R206  +   
[207-224] K208 or K211 or R224  +   
[209-224] K211 or R224  +   
[225-239] K239  +   
[240-247] R246 or K247   +  
[247-267] K247 or K264 or R267  + + + 
[248-267] K264 or R267 + + +  
[268-285] R285  +   
[286-294] R294  + + + 
[286-300] R294 or K295 or K300  + +  
  
D C30 C60 B 
[295-313] K295 or K300 or K313 + + + + 
[296-300] K300   +  
[296-313] K300 or K313 + + +  
[314-328] K328  +   
[329-334] R334   +  
[329-348] R334  + +  
[329-351] R334 or K348 or K351  + +  
[335-348] K348  + +  
[335-351] K348 or K351  +   
[349-367] K351 or K353 K367  +   
[352-367] K353 or K367  + +  
[354-367] K367   +  
[354-376] K367 or K374 or R376   +  
[368-374] K374   +  
[368-376] K374 or R376 + + + + 
[375-395] R376 or R395  +   
[396-410] R410  + +  
[411-421] R421   +  
[422-436] K422 or K426 or R436 + + +  
[423-436] K426 or R436 + + +  
[427-436] R436  + +  
[427-445] R436 or R445 + + +  
[446-478] K458 or K471 or R478 +  +  
[459-471] K471  + +  
[459-478] K471 or R478     
[472-479] R478 or K479   +  
[472-483] R478 or K479 or K483  + +  
[479-491] K479 or K483 or R485    + 
[480-491] K483 or R485  + + + 
[484-491] R485 + + +  
  
    
 
 
Table 6: Monitored glycated residues located on the Bβ-chain of fibrinogen 
The positions of detected peptides are written in brackets. D, digest; C30, C30-silica, C60, 
C60(30); B, boronate phase 
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D C30 C60 B 
[  1-  8] R8   +  
[  9- 31] R31 +    
[ 62- 79] K64 or K79  + +  
[ 65- 79] K79 + + +  
[ 65- 84] K79 or K84 + + +  
[ 89-113] K101 or K111 or R113 + +   
[112-121] R113 or K114 or K121     + 
[114-121] K114 or K121  +  + 
[115-121] K121 + + +  
[122-134] R134  + +  
[122-146] R134 or K146 + + +  
[135-151] K146 or K151  +   
[135-153] K146 or K151 or K153  + + + 
[147-153] K151 or K153  +   
[152-166] K153 or K166 + +   
[167-177] K177  + +  
[167-188] K177 or K185 or K188  + + + 
[178-199] K185 or K188 or K196 or K199    + 
[189-199] K196 or K199   +  
[200-223] K222 or R223 + + +  
[224-231] K231   +  
  
D C30 C60 B 
[224-232] K231 or K232 + + +  
[224-238] K231 or K232 or K238  +   
[232-238] K232 or K238 + + + + 
[233-258] K238 or K258  + +  
[259-273] R273  +   
[259-282] R273 or R282  + +  
[274-292] K292  + +  
[274-299] R282 or K292 or K299    + 
[283-299] K292 or K299  + +  
[293-301] K299 or R301 + + +  
[329-347] K347 +    
[348-364] K364  +   
[365-401] K382 or K399 or R401   +  
[400-406] R401 or K406  + +  
[400-407] K406 or K407 + +  + 
[402-406] K406   +  
[402-411] K406 or K407 or K411  + +  
[407-417] K407 or K411 or R417    + 
[408-417] K411 or R417 + + + + 
[412-417] R417  +   
[418-432] K432 + + +  
 
Table 7. Monitored glycated residues located on the c-chain of fibrinogen 
The positions of detected peptides are given in brackets. D, digest; C30, C30-silica, C60, 
C60(30); B, boronate phase 
 
 
 
Forty-one possible glycated sites were found for the c-chain of fibrinogen. Of these, 24 were 
recognised from the digest. Results achieved using C30-silica (33) and C60(30) (34) were 
similar to each other. With the boronate tip 21 glycated sites were determined (Table 7). As it 
was expected on the basis of previous results with phosphopeptides, Tables 5–7 above 
demonstrate the numerous, hydrophilic peptides glycated at arginine residues and containing 
less than ten amino acids bound only on C60(30). For instance, glycations on R8, R35, R123, 
R246 and R421 residues were only possible to be explored employing C60(30). 
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4.2 Results of the experiments of the boronate affinity chromatography 
The method used for the enrichment of boronate affinity chromatography has never 
been optimized before. In these chapters the results of the optimization (binding and elution 
conditions) can be seen and the application of boronate affinity enrichment for patients 
suffering from type 2 diabetes mellitus is compared to that in healthy volunteers. 
 
 
4.2.1 Evaluation of binding conditions of boronate affinity tips 
Electrochemical measurements proved to be a useful approach to optimize the ionic 
strength and pH of the binding buffer as well as the most appropriate circumstances of 
elutions. Figure 16/A below displays the effect of the pH of binding buffer on the amount of 
eluted glucose. These results clearly demonstrate that the affinity tips bind the highest amount 
of glucose when the pH of the binding buffer varies between 7.7 and 8.2. Further 
enhancement of the pH of the binding buffer results in a decrease of the bound glucose. The 
maximal binding capacity of the tips was found to fall within the pH range of 7.8–8.2 in the 
curve; therefore, a value of approximately 8.2 was selected for this study. As demonstrated by 
Figure 16/B below, when the binding capacity of the tips was plotted against the ionic 
strength of the binding buffer, 150 mM ammonium chloride provided the best results. These 
results can be regarded as consistent with data described previously [54, 69]; however, the 
previously reported values were not based on quantitative evidence. Figure 16/C below shows 
the effect of the pH of the eluent depicted in the function of the eluted glucose when using 
solutions of formic acid at different pH values for the elution. This relation is exponential; the 
lower the pH of the eluent, the higher the amount of glucose eluted. The elution of bound 
glucose on boronate-derivatised resin can also be accomplished by means of a highly 
concentrated sorbitol solution. The effects of the concentrations of sorbitol solution are 
plotted against the amount of released glucose in Figure 16/D below. The curve reaches a 
plateau at 1.2 M; therefore, there is no need to employ sorbitol solutions for the elution at 
higher concentrations.  
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Figure 16: A.) Relationship between the bound glucose and the pH of the binding buffer B.) 
Amount of bound glucose plotted in the function of the ionic strength of binding buffer C.) 
Elution of glucose by formic acid at different pH values D.) Elution of glucose with sorbitol 
solution at different concentrations 
 
 
4.2.2 Evaluation of performance of boronate affinity tips toward glycated 
peptides enriched from glycated RNase A and HSA tryptic digests 
The application of the boronate affinity tips was introduced employing in-vitro 
glycated HSA and RNase A as model proteins. Figure 17/B shows the effect of the time of 
incubation with glucose on the degree of the modification of proteins. This can be calculated 
from the mass shift measured between the unmodified and glycated proteins. Taking into 
account the fact that the condensation of 1 glucose unit can cause approximately a 162 Da 
mass increase in comparison with the unmodified proteins (Figure 17/A), glycation of RNase 
A for 14 days clearly represents that, on the average, 1-2 glucose units were condensed on an 
RNase A molecule. 
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HSA was incubated with a high concentration of glucose in PBS buffer for 12 and 28 
days. The reason why the shorter incubation time was also chosen is that in patients being 
poorly controlled and suffering from type 2 diabetes mellitus the HSA is also glycated, but the 
number of glucose moieties condensed on an HSA molecule is not consistent with an 
overglycated HSA (incubated for 28 days). In contrast to Figure 17/C below, where the mass 
spectrum of the non-glycated HSA is shown, Figure 17/D indicates a mass shift of 1050 Da. 
This means that, on the average, 6 or 7 glucose moieties are attached to an HSA molecule. 
Therefore, HSA glycated for 12 days can be considered as a model of HSA being glycated 
due to the elevated blood glucose level and isolated from patients under poor diabetic control 
[95]. Figure 17/E below represents a mass spectrum belonging to the overglycated HSA. The 
corresponding mass shift shows that approximately 31 glucose moieties are attached to an 
HSA molecule. This result is relevant to the results reported in previous studies [67, 95]. 
 
 
Figure 17: Effect of glycation on molecular weight of proteins. (A) Mass spectrum of 
unglycated RNase A. (B) Mass spectrum of RNase A glycated for 14 days. (C) Mass 
spectrum of unglycated HSA. (D) Mass spectrum of HSA glycated for 12 days. (E) Mass 
spectrum of HSA glycated for 28 days. Each spectrum was acquired in linear mode and a sum 
of 1000 shots. The applied matrix was SA. a.u., i.e. arbitrary units. 
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Evaluation of the results measured for the glycated peptides was carried out using a 
software developed and first employed by Böddi et al. (www.fraki.lgx.hu) [94]. The 
comparison of two series of masses—the in-silico generated and the measured—can be 
carried out within a mass tolerance range of 50–150 ppm. In this study, 100 ppm mass 
tolerance was permitted. If the measured values provided higher margins compared to in-
silico masses, they were not included in the group of identified peptides. Further identification 
of glycated constituents occurred in their post-source decay spectra. Post-source decay spectra 
of the glycated peptides yield a specific fragmentation pattern so long as neutral losses of a 
dehydrated glucose (M+H+–162) and a fragment of a glucose (M+H+–120) serve as a basis 
for the identification of the modification. From these two neutral losses, the structure of 
C4H8O4 can be assigned to the latter. Moreover, the series of y-ions appearing in the low mass 
range furnishes important information about the sequence of the peptide of interest. 
 
Although the mixture of two matrices (CHCA and DHB) was proposed to be used 
for the analysis of peptides modified with sugars, for the glycated peptides DHB matrix at a 
concentration of 25 mg×ml-1 was proven to be better in terms of the number of monitored 
peptides and the sites of modifications localized in them. For instance, when the enrichment 
of a 20 pmol digest of HSA glycated for 28 days was carried out using ammonium 
chloride/ammonia as binding buffer and the eluate was desalted on C60(30) particles after the 
elution of glycated peptide, the application of DHB resulted in 41 single glycated peptides, 
contrary to the mixture of DHB and CHCA, where only 30 were found. This comparison was 
measured for each experiment conducted throughout this study, and in all cases DHB was 
considered as a more suitable matrix than the mixture.  
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Figure 18: Workflow of different approaches throughout the application of boronate affinity 
enrichment for glycated peptides 
 
Figure 18 above demonstrates the workflow accomplished throughout the application 
of boronate affinity tips. As can be seen, glycated authentic proteins underwent tryptic 
digestion. The optimized conditions, including the ionic strength and pH of the binding buffer 
and the ways of the different types of elutions, were applied for HSA glycated for 28 days. 
This is why the highest number of glycated peptides is expected in this case; therefore, the 
differences among the applied approaches taken are obviously better expressed. Results 
received from the experiments carried out with a sorbitol solution at a concentration of 1.2 M 
were evaluated first. Under optimized conditions, the binding of the glycated peptides was 
carried out using ammonium chloride/ammonia buffer and with taurine buffer using both at 
the same pH value (8.2) and the same concentration (150 mmol). After the elution of glycated 
peptides with sorbitol prior to MALDI–TOF analysis, the eluate consequently needed to be 
desalted. This was implemented using three different types of sorbents: the commercially 
available ZipTip, fullerene(C60)-derivatised silica material (C60(30)) [42] and the one made 
on the basis of silica with a 30-nm pore radius), and a homemade densely coated C18 silica 
[96]. The two latter types were evaluated in detail in SPE experiments carried out to separate 
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tryptic peptides and their glycated derivatives in the previous work. Results of that work 
provided a line of evidence for the excellent binding affinity of C60(30) toward constituents 
with enhanced hydrophilic properties such as glycated peptides [94]. The experimental 
circumstances, including the composition of the binding buffer, the comparison of the elution 
using sorbitol and formic acid, and the different types of sorbents employed for desalting 
the eluates after using a sorbitol solution at a concentration of 1.2 M, were evaluated on the 
basis of the identified single and double glycated peptides and the number of possible 
glycated sites on HSA glycated for 28 days. These can be plotted by means of Venn diagrams. 
Figure 19/A and B below depict the numbers of single glycated peptides captured by the 
boronate affinity tips employing ammonium chloride/ ammonia buffer and taurine buffer, 
respectively, for the enrichment of glycated constituents. In both cases, the bound glycated 
peptides were eluted with a highly concentrated sorbitol solution (1.2 M) and desalted on the 
three materials mentioned above. As shown in the number of glycated peptides bound and 
eluted from each sorbent, ammonium chloride/ammonia buffer proved to be more efficient 
than taurine buffer in that 67 single glycated peptides could be selectively captured by means 
of using ammonium chloride/ammonia buffer, whereas 55 peptides modified with only 1 
sugar unit were possible to be monitored after the elution from all of the employed phases. 
The evaluation of binding buffers was also implemented for glycated peptides modified at two 
amino acid residues with D-glucose (double glycated peptides). 
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Figure 19: Comparison of different sorbents used for desalting when elution is carried out 
with sorbitol. (A) Venn diagram showing the numbers of detected single glycated peptides 
when the loading buffer was ammonium chloride/ammonia at optimized circumstances. (B) 
Venn diagram depicting the numbers of detected single glycated peptides in the case of using 
taurine buffer. (C) Venn diagram of possible glycated sites monitored from single glycated 
peptides bound by means of ammonium chloride/ammonia buffer. (D) Venn diagram of 
possible glycated sites monitored from single glycated peptides bound using taurine buffer. 
 
 
The results demonstrated in Figures 20/A and B below confirm the observation made in the 
case of single glycated peptides. It was possible to bind 42 double glycated peptides 
selectively by applying an ammonium chloride/ammonia buffer. Considerably fewer (33) 
double glycated peptides were successfully monitored in the case of taurine buffer. Not only 
do the numbers of bound modified constituents indicate the effect of the binding buffers on 
the efficiency of the enrichment but also the numbers of possible modification sites located in 
the bound peptides must be taken into account by the evaluation. In single glycated peptides, 
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78 possible sites of modification were recognized using ammonium chloride/ammonia buffer 
(Figure 19/C below) and 68 glycated residues were identified by means of taurine buffer 
(Figure 19/D below). Regarding the glycated sites identified, in double modified peptides 
only a slight difference is observed in the number of glycated residues when comparing the 
two loading buffers. The use of the binding buffer consisting of ammonium chloride and 
ammonia allowed us to identify 63 potential glycated sites from those peptides captured by 
boronate affinity tips (Figure 20/C). In comparison, taurine buffer is capable of assisting with 
binding peptides to affinity tips, from which 60 glycated sites could have been determined 
(Figure 20/D below). In conclusion, the choice of an ammonium chloride/ammonia buffer 
with optimized pH and ionic strength enables binding more glycated peptides than the 
extensively used taurine buffer with the same pH and concentration.  
 
 
 
Figure 20: Comparison of different sorbents used for desalting when elution is carried out 
with sorbitol. (A) Venn diagram showing the numbers of detected double glycated peptides 
when the loading buffer was ammonium chloride/ammonia under optimized circumstances. 
(B) Venn diagram demonstrating the numbers of double glycated peptides detected in the case 
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of using taurine buffer. (C) Venn diagram of the possible glycated sites detected in double 
glycated peptides bound by means of ammonium chloride/ammonia buffer. (D) Venn diagram 
of the possible glycated sites detected in double glycated peptides bound employing taurine 
buffer. 
 
 
It is important to emphasize that the differences in using these buffer systems are not 
expressed in the number of bound peptides and the identified glycated sites exclusively. For 
instance, after the binding of glycated peptides by applying both buffer systems, the elution of 
the bound constituents was accomplished with a sorbitol solution. This was followed by a 
desalting step using SPE cartridges filled with C60(30) silica particles. After the desalting 
step, 13 unique peptides of the total single glycated peptide pool adsorbed by the C60(30) 
particles (from 41 peptides) were possible to acquire using ammonium chloride/ammonia as 
binding buffer (Figure 19/A). Figure 19/B above shows unique single glycated peptides also 
bound exclusively by C60(30) particles when the enrichment of the glycated peptides was 
carried out using taurine buffer. In total, 43 of the eluted peptides could be identified when 
desalting them by means of employing C60(30) silica material. Of 43 single glycated 
peptides, 15 were identified only from the eluate of C60(30) and the remaining 28 peptides of 
the other sorbents could also be detected. It may be important to emphasize that these 15 
unique glycated peptides must be interpreted only in the context of evaluating the three 
different sorbents with respect to the number of bound single glycated peptides. If the unique 
peptides detected in the eluates of C60(30) SPE material after the enrichment with the two 
above-mentioned buffer systems are compared, it can be concluded that their numbers were 
very similar to each other so long as 13 of them were found when enriching them with an 
ammonium chloride/ammonia buffer and 15 glycated peptides were found when the binding 
buffer was composed of taurine. Only 5 single glycated peptides with the same sequence and 
modifications could be analyzed from the unique peptides enriched with the two buffers and 
desorbed from C60(30). The majority of the unique peptides were found to be different 
despite the fact that they had been eluted from the same sorbent. This observation reveals that 
the use of different buffer systems alters the selectivity of the boronate phase insofar as the 
captured peptide profile and the identified potential glycated sites show great variety. 
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A) Single glycated peptides
 
Location 
 
C60 
(30) 
Zip 
Tip 
C18 
silica 
unique peptides 13 12 9 
 
unique sites  8 4 5 
[  5- 20] R10 or K12 or K20 +   
[ 82- 98] K93 or R98  +  
[ 99-114] K106 or R114 +   
[115-136] R117 or K136  +  
[137-145] K137 or R144 or R145   + 
[161-181] K162 or K174 or K181 +   
[175-181] K181  +  
[198-209] K199 or K205 or R209   + 
[200-212] K205 or R209 or K212   + 
[206-212] R209 or K212  +   
[223-233] K225 or K233    + 
[226-233] K233  +  
[241-262] R257 or K262 +   
[275-286] K276 or K281 or K286    + 
[314-323] K317 or K323    + 
[318-336] K323 or R336   +  
[324-336] R336 +   
Location 
 
C60 
(30) 
Zip 
Tip 
C18 
silica 
[338-351] R348 or K351  +   
[352-372] K359 or K372  +   
[360-389] K372 or K378 or K389 +   
[390-410] K402 or R410   +  
[403-414] R410 or K413 or K414 +   
[411-428] K413 or K414 or R428  +  
[415-432] R428 or K432   +  
[429-439] K432 or K436 or K439 +   
[446-466] K466 +   
[476-484] R484   + 
[501-524] K519 or R521 or K524  +  
[520-525] K524 or K525  +  
[526-541] 
K534 or K536 or K538 or 
K541  +  
[535-545] 
K536 or K538 or K541 or 
K545 +   
[539-557] K541 or R545 or K557  +  
[546-564] K557 or K560 or K564   + 
[565-585] K573 or K574    + 
 
B) Double glycated peptides
 
Location 
 
C60 
(30) 
Zip 
Tip 
C18 
silica 
unique peptides 13 11 6 
 
unique sites  7 13 4 
[ 94-114] R98 or K106 or R114   + 
[ 99-136] 
K106 or R114 or R117 
or K136 +   
[138-145] R144 and R145   +  
[161-181] K162 or K174 or K181  +  
[163-181] K174 and K181 +   
[182-190] R186 and K190  +  
[187-195] K190 and K195  +   
[213-225] R218 or R222 or K225 +   
[234-262] K240 or R257 or K262  +  
[258-276] K262 or K274 or K276  +  
[263-286] 
K274 or K276 or K281 
or K286  +   
[275-286] K276 or K281 or K286  +  + 
[277-286] K281 and K286   + 
Location 
 
C60 
(30) 
Zip 
Tip 
C18 
silica 
[318-337] K323 or R336 or R337  +  
[360-389] K372 or K378 or K389  +  
[373-402] K378 or K389 or K402  +  
[411-428] K413 or K414 or R428   + 
[429-436] K432 and K436  +  
[429-439] K432 or K436 or K439 +   
[433-444] K436 or K439 or K444 +   
[437-444] K439 and K444   + 
[467-475] R472 and K475  +  
[476-500] R484 or R485 or K500 +   
[485-521] 
R485 or K500 or K519 
or R521 +   
[501-524] K519 or R521 or K524 +   
[520-525] K524 and K525  +  
[522-534] K524 or K525 or K534   + 
[542-560] R545 or K557 or K560 +   
[546-560] K557 and K560  +   
 
Table 8: Detected single and double unique glycated peptides in the case of using ammonium 
chloride/ammonia binding buffer. Peptides were released from tips using sorbitol and desalted 
on C60(30), ZipTip, and homemade C18 silica. Italic bold type indicates unique glycation 
sites. 
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Tables 8 and 9 above provide detailed information about the unique glycated peptides 
and the locations of the recognized possible glycated sites of these peptides. Using 
ammonium chloride/ammonia buffer for the enrichment of glycated constituents with 
boronate affinity tips, as described earlier in this study, 41 single and 24 double glycated 
peptides were bound by C60(30) silica particles. In addition, 13 single and 13 double glycated 
unique peptides were explored in the eluted peptide pool. Single glycated peptides involve 8 
possible glycated sites, namely K106, R114, R257, R348, K372, K436, K439, and K466, 
whereas 7 unique sites modified with D-glucose, namely R218, R484, R485, K500, K519, 
R521, and K560 were identified from double glycated peptides (Figures 19 and 20 above and 
Table 8 above).  
 
These results were compared with those received after the enrichment of glycated peptides 
using taurine buffer. Among those peptides released from the affinity tips and desalted from 
the sorbitol solution on C60(30) particles, 15 single and 5 double glycated unique peptides 
were analyzed. Single glycated peptides made possible the identification of 9 unique glycated 
sites. Surprisingly, of the 5 double glycated unique peptides, 8 possible unique modified sites 
were recognized, as shown in Figures 19 and 20 above and Table 9 below. In single glycated 
unique peptides K190, K372, K413, K444, R445, K466, K536, K538, and K541, unique 
glycated sites were localized. In double glycated unique peptides, residues at R81, K93, R218, 
K372, K378, K389, R445, and K466 were likely to undergo non-enzymatic glycation.  
ZipTip is a commercially available product, probably the most frequently and 
efficiently used tool for desalting the solutions of proteins and peptides prior to mass 
spectrometric measurements. In previous studies, the superiority of C60(30) to other 
commercial products such as Oasis and Sep-Pak and some octadecyl and triaconthyl modified 
silica material with high surface coverage has been reported in terms of SPE experiments of 
different biomolecules, including peptides, proteins, phosphorylated peptides, and glycated 
peptides [42]. Through the present work, an idea of trying to first use ZipTip for desalting 
glycated peptides emerged. When binding peptides to affinity tips with ammonium 
chloride/ammonia buffer, the desalting procedure carried out with ZipTip allowed the 
identification of 12 single glycated unique peptides modified at the residues of K93, R98, 
K402, and K524. Thus, in terms of the number of unique glycated sites localized in single 
unique glycated peptides, ZipTip does not seem to be as efficient as C60(30); however, it 
must be noted that 42 single glycated peptides were desalted by means of ZipTip, and 58 
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possible glycated sites were monitored. In addition, the analysis of 11 double glycated unique 
peptides comprising 13 glycated unique sites was made possible by ZipTip. These peptides 
were modified at the residues of R144, R145, K162, R186, R257, K262, K323, K372, K378, 
K389, K402, R472, and K475. 
 
A) Single glycated peptides
 
Location 
 
C60 
(30) 
Zip 
Tip 
C18 
silica 
unique peptides 15 8 4 
 
unique sites  9 6 0 
[115-136] R117 or K136 +   
[115-137]a R117 or K136 or K137    + 
[115-144] 
R117 or K136 or K137 or 
R144  +  
[161-181] K162 or K174 or K181 +   
[163-174] K174 +   
[163-181] K174 or K181    
[175-181] K181 +   
[175-186] K181 or R186    
[175-190] K181 or R186 or K190 +   
[200-212] K205 or R209 or K212   + 
[206-212] R209 or K212  +   
[226-257] K233 or K240 or R257 +   
[241-262] R257 or K262  +  
[241-274] R257 or K262 or K274   + 
Location 
 
C60 
(30) 
Zip 
Tip 
C18 
silica 
[258-276] K262 or K274 or K276  +  
[275-286] K276 or K281 or K286    + 
[287-323] K313 or K317 or K323  +  
[314-323] K317 or K323   +  
[352-372] K359 or K372  +   
[390-402] K402    
[390-410] K402 or R410   +  
[403-414] R410 or K413 or K414 +   
[411-428] K413 or K414 or R428 +   
[415-432] R428 or K432   +  
[440-445] K444 or R445 +   
[446-466] K466 +   
[485-519] R485 or K500 or K519   +  
[526-541] 
K534 or K536 or K538 or 
K541 +   
[539-557] K541 or R545 or K557 +   
[542-560] R545 or K557 or K560 +   
 
B) Double glycated peptides
 
  
C60 
(30) 
Zip 
Tip 
C18 
silica 
unique peptides 5 7 7 Location 
unique sites  8 12 8 
[  5- 12] R10 and K12    + 
[ 74- 98] R81 or K93 or R98 +   
[ 94-114] R98 or K106 or R114  +  
[ 99-136] K106 or R114 or R117 or K136  +  
[115-136] R117 and K136 +   
[145-160] R145 or K159 or R160  +  
[161-181] K162 or K174 or K181   + 
[163-181] K174 and K181  +  
[213-222] R218 and R222 +   
  
C60 
(30) 
Zip 
Tip 
C18 
silica 
[223-240] K225 or K233 or K240   + 
[263-286] K274 or K276 or K281 or K286    + 
[360-389] K372 or K378 or K389 +   
[414-428] K414 and R428   +  
[437-444] K439 and K444  +  
[445-466] R445 and K466 +   
[526-538] K534 or K536 or K538 or K541  +  
[539-557] K541 or R545 or K557   + 
[561-573] K564 and K573    + 
[561-574] K564 or K573 or K574   + 
 
Table 9: Detected single and double unique glycated peptides in the case of using taurine 
binding buffer. Peptides were released from tips using sorbitol and desalted on C60(30), 
ZipTip, and homemade C18 silica. Italic bold type indicates unique glycation sites. a Peptide 
in the sequence brackets [115–137] could be detected from the digest of nonglycated HSA 
(standard). 
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Concerning taurine binding buffer, for single glycated peptides, ZipTip provided a 
worse result than C60(30) so long as only 30 peptides were bound; of these, 8 were found to 
be unique. Taking into account the glycated residues detected in peptides bound on ZipTip, 54 
possible glycated sites were found, in contrast to C60(30), where this number was slightly 
higher (61). Six unique glycated sites at the positions of K402, K432, K313, K317, K500, and 
R485 could be observed. Regarding the number of double glycated peptides, ZipTip proved to 
be as efficient as C60(30) insofar as both sorbents were capable of binding 16 peptides. For 
ZipTip, 7 unique double glycated peptides with 12 unique sites at K106, R114, R145, K159, 
R160, K414, R428, K439, K444, K534, K536, and K538 were detected. 
Finally, the desalting of the glycated peptides was also tried with octadecyl silica with 
high surface coverage. In the case of ammonium chloride/ammonia buffer 36 single glycated 
peptides were successfully bound, 9 of which were unique peptides, modified at K199, K317, 
K276, K564, and K573 as well. Using this buffer, only 13 double glycated peptides could be 
desalted. The poor performance of this material toward hydrophilic glycated peptides is also 
expressed in the number of unique peptides found, that is, only 6 with 4 possible unique 
glycated sites at R98, K413, K414 and R428. When using taurine buffer, the results of the 
desalting on C18 particles were even worse. In total, 28 single glycated peptides of the 4 
unique peptides analyzed were bound; none of them comprised any unique glycated sites. In 
total, 17 double glycated peptides could be identified; of these, 7 proved to be unique with 8 
possible sites of glycation at R10, K12, K162, K274, K276, K564, K573, and K574. 
 
Elution of the bound constituents is frequently implemented in acidic media. As 
reported earlier [69], a formic acid solution of pH 2.0 proved to be the best in terms of the 
amount of eluted D-glucose evidenced by amperometric measurements. Elution with this 
solution was compared to elution implemented with sorbitol (desalted by C60(30)) regarding 
the number of eluted single and double glycated peptides and the possible identified glycated 
sites as well. These two ways of elution were compared with the digest of HSA incubated 
with D-glucose for 28 days to assess the efficiency of the enrichment. Surprisingly, the 
elution with formic acid yielded the worst results in terms of the number of identified glycated 
peptides and the possible sites of glycations. 
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Figure 21: Comparison of elutions of glycated peptides from affinity tips with digest of HSA 
glycated for 28 days with the numbers of detected glycated peptides indicated. (A) Venn 
diagram showing the numbers of single glycated peptides when using ammonium 
chloride/ammonia binding buffer. (B) Venn diagram of the single glycated peptides released 
from the tips in the case of employing taurine binding buffer. (C) Venn diagram of the double 
glycated peptides detected when using ammonium chloride/ammonia buffer. (D) Venn 
diagram depicting double glycated peptides comparing the elutions with the digest when the 
binding buffer was taurine. 
 
 
Figure 21/A above shows that in 100 pmol of the digest of overglycated HSA without 
enrichment, 29 single glycated peptides were recognized and 3 were found to be unique 
peptides with 5 unique glycated sites. When binding glycated peptides with ammonium 
chloride/ ammonia buffer, the elution of single glycated peptides with formic acid resulted in 
the release of 27 single glycated peptides from the boronate affinity tips; of these, 7 were 
unique peptides with 4 possible sites of modification. As mentioned earlier, the elution with 
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sorbitol yielded the detection of 41 single glycated peptides; nevertheless, the eluate was 
subjected to SPE on C60(30) particles prior to MALDI–TOF analysis. However, in this 
context of the comparison, 15 unique peptides comprising 12 unique residues were explored. 
Using the same buffer, the same trend could be observed for double glycated peptides given 
that 14 of them were identified from the digest (only 3 of them were unique with 3 unique 
sites). As also demonstrated in Figure 21/B above, formic acid made possible the release of 
only 11 peptides. Of these double glycated peptides, 3 were found to be unique, including 5 
unique sites of glycation. Elution with sorbitol again showed the best results after desalting. 
This was expressed by 24 identified peptides; of these, 14 were observed to be unique 
constituents containing 16 unique glycated sites. 
Figure 21/C and D above show those cases where glycated peptides were bound to the 
affinity tips in the presence of taurine buffer. Briefly, from the digest, 29 single glycated 
peptides were detected; of these, 6 were unique and each had 3 unique residues. Eluting the 
peptides with formic acid solution allowed the recognition of 31 single glycated peptides; of 
these, 8 were unique with 4 possible unique sites of glycation. When eluting the peptides with 
sorbitol, 43 single glycated peptides could be detected; of these, 15 were unique and 
incorporated 8 unique glycated sites. With respect to double glycated peptides in the case of 
using taurine buffer, 14 were found in the digest; of these, 8 were unique with 8 unique 
residues. Whereas elution with formic acid provided 9 double glycated peptides (4 of these 
were unique with 7 unique sites), elution accomplished with sorbitol caused the release of a 
considerably higher number of peptides so long as 16 of them could be measured after 
desalting (10 of these proved to be unique and comprised peptides of 13 unique glycated 
sites). As demonstrated above, with the elution of the bound glycated peptides with formic 
acid solution, it seems that no enrichment of the modified constituents occurred in spite of the 
fact that the highest amount of glucose could be measured at pH 2.0 (as discussed earlier in 
Section 4.2.1). Therefore, the acidic elution is not recommended by Takátsy et al.. 
The most efficient way to gain information about the modified glycated sites of a 
protein by MALDI–MS is to bind glycated peptides from the digest of the protein using, for 
instance, ammonium chloride/ammonia binding buffer under optimized circumstances, and 
then the selectively bound constituents are eluted with a concentrated solution of a proper 
sugar such as sorbitol. Furthermore, prior to analysis, the presence of undesirable sugar can be 
eliminated using an effective sorbent for desalting. As was demonstrated, C60(30) proved to 
be as efficient as ZipTip; no significant differences could be observed in the binding efficacy 
of either phase toward glycated peptides. 
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Although the methods described above were evaluated on the basis of the number of 
unique peptides and glycated sites, some of these modifications could be present in the 
nonglycated HSA standard because it was isolated from human serum. Therefore, if the aim 
of the work is also to identify those possible glycated sites modified only after the in-vitro 
glycation, the analysis of the digest of non-modified HSA is also an important requirement. 
These glycated peptides present in the digest of non-modified HSA probably comprise the 
most privileged accessible residues; therefore, their identification — especially after the non-
enzymatic glycation (when their amounts in the digest are increased immensely) — is not a 
challenging task. If these peptides are taken into account, the sensitivity of the given method 
is undermined. The analysis of the digest of non-glycated HSA allowed us to identify 11 
peptides by means of using ammonium chloride/ammonia as a binding buffer; this was 
followed by an elution with sorbitol, and the eluate was desalted using both C60(30) and 
ZipTip (see Table 10). As was expected, elution with formic acid made possible the 
identification of only 2 peptides, both of which could be analyzed from the eluates with 
sorbitol. It is also worth noting that 4 of these peptides contain K233, K378, K525 and K545 
glycated residues and these residues are well known to be privileged and are able to be 
glycated easier [67, 81, 94]. From the digest of unglycated RNase A, no glycated peptides 
were monitored. 
 
   
C60 
(30) ZipTip HCOOH 
  
glycated peptides 8 8 2 
  
possible glycated sites 16 17 4 
[ 65- 81] K73 or R81 SLHTLFGDKLCTVATLR + +  
[115-137] R117 or K136 or K137  LVRPEVDVMCTAFHDNEETFLKK + +  
[137-144] K137 or R144  KYLYEIAR +   
[210-218] K212 or R218  AFKAWAVAR + +  
[226-240] K233 or K240 AEFAEVSKLVTDLTK + + + 
[337-348] R337 or R348 RHPDYSVVLLLR +   
[373-389] K378 or K389 VFDEFKPLVEEPQNLIK  +  
[414-428] K414 or R428  KVPQVSTPTLVEVSR +   
[501-521] K519 or R521  EFNAETFTFHADICTLSEKER  +  
[525-534] K525 or K534  KQTALVELVK + + + 
[542-557] K545 or K557 EQLKAVMDDFAAFVEK  +  
 
Table 10: Glycated peptides identified from the digest of non-glycated HSA. Elutions of the 
bound constituents have been carried out using sorbitol and formic acid. The applied binding 
buffer was ammonium chloride/ammonia. 
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The usefulness of the method proposed by Takátsy et al. is clearly demonstrated in 
Figure 22 below. Figure 22/A below shows the MALDI spectrum of the digest of HSA 
(glycated in-vitro for 28 days) in the range from 2000 to 2230 Da. Besides a very intensive 
non-modified tryptic peptide appearing at m/z 2086.46, 2 less intensive glycated peptides can 
be observed at m/z 2060.68 and 2013.56. Moreover, the mass accuracy of these peptides is 
not reliable due to the very low signal- to-noise ratio of the first peptide. The latter does not 
possess very good mass resolution, which can be ascribed to the fact that peptides with similar 
masses can have a disturbing effect on mass resolution. Figure 22/C below shows the 
spectrum belonging to the digest of HSA glycated for 28 days after having been enriched by 
the method proposed above. Four glycated peptides can be seen in the figure. The peak 
appearing at m/z 2061.05 is a single glycated peptide. Additional peaks at m/z 2094.06, 
2104.03, and 2217.24 are double glycated peptides, and their sequences are also shown in 
Figure 22/C below. When the profile of glycated peptides enriched from HSA glycated for 12 
days (Figure 22/B) is compared to the results of enrichment from the digest of HSA glycated 
for 28 days (Figure 22/C), significant differences can be found. For example, as a result of the 
enrichment from the digest made from HSA glycated for 12 days, 3 double glycated peptides 
were monitored at m/z 2094.28, 2104.09, and 2207.45. The rather intensive single glycated 
peptide detected in the digest of HSA glycated for 28 days at m/z 2061.05 could not be 
detected from the digest of HSA glycated for 12 days. This means that this glycation site must 
be more hindered; therefore, it needs to be exposed longer to the high concentration of sugar. 
This observation is also relevant to the peptide detected at m/z 2217.25 from the digest of 
HSA glycated for 28 days. In contrast, the peptide detected at m/z 2207.45 from the digest of 
HSA glycated for 12 days clearly indicates that this peptide, comprising one of the most 
privileged glycation sites (K378) [26], was modified relatively rapidly and that further 
oxidation processes are responsible for the absence of this peptide in the spectrum. 
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Figure 22: Enrichment of glycated peptides. (A) Mass spectrum of digest of HSA glycated 
for 28 days. No enrichment was used. (B) Mass spectrum of digest of HSA glycated for 12 
days after selective enrichment. (C) Mass spectrum of digest of HSA glycated for 28 days 
after selective enrichment. In both cases, the enrichment was carried out using ammonium 
chloride/ammonia binding buffer and the elution of the bound peptides was carried out with 
sorbitol. Prior to MALDI measurement, the eluates were desalted on C60(30) particles. Each 
spectrum was monitored in reflectron mode and a sum of 1000 shots. The applied matrix was 
DHB. Asterisks (*) denote the glycated peptides. a.u., i.e arbitrary units. 
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Previously published studies have reported the investigation of glycated peptides 
employing LC–tandem mass spectrometry (MS/MS) techniques [10, 26]. The advantages of 
using these approaches in comparison with different off-line MALDI methods are that the loss 
of samples is largely reduced so long as the separated peptides are analyzed on-line by mass 
spectrometric methods. Table 11 indicates glycated peptides identified by Takátsy et al. from 
the digest of HSA glycated in-vitro for 28 days. Takátsy et al. pointed out that to the best of 
their knowledge, this is the first attempt to separate glycated peptides on a monolithic 
capillary column. The results are very similar to those reported in previous studies concerning 
the number of glycated peptides and the possible modified residues [81]. 
 
 
Location Glycation site 
 
[ 42- 64] K51 or K64  
[160-174] R160 or K162  or K174 + 
[226-240]a K233 or K240  
[258-274] K262 or K274  
[263-276] K274 or K276   
[318-336] K323 or R336   
[349-359] K351 or K359  
[373-389]a K378 or K389  
[390-402] K402  
[414-428]a K414 or R428   
[473-484] K475 or R484   
[525-534]a K525 or K534   
[539-557] K541 or R545 or K557 * 
[542-557]a K545 or K557  
 
Table 11: Glycated residues identified by LC–MS. 
The plus sign (+) means that in that region of HSA both single and double glycated peptides 
were detected. The asterisk (*) denotes a double glycated peptide while a indicates that the 
peptide could be detected from the digest of nonglycated HSA. 
 
 
Table 11 above shows that 13 of the 15 glycated peptides identified, were found to be 
single glycated and only 2 were modified with 2 glucose units. However, the table also shows 
that 5 of all the identified peptides also were present from the digest of the non-glycated HSA. 
This fact clearly indicates that despite using a highly efficient separation method, the efficacy 
of this method is overcome by the boronate affinity chromatography/off-line MALDI–TOF 
method introduced before. The peptides identified allowed us to localize 28 possible glycation 
sites. This proved to be better than previously reported data; of 15 peptides, 22 possible sites 
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of modification were described by Ref. [81, 97]. However, both LC–MS methods were able to 
recognize the privileged K233, K276, K378, K545, and K525 sites of glycation. 
Table 12 below shows peptides and glycation sites of RNase A recognized by 
boronate affinity tips (using ammonium chloride/ammonia buffer). The bound peptides were 
eluted with sorbitol and desalted on C60(30) particles. As can be seen, by means of affinity 
tips, 5 single and 2 double glycated peptides comprising 12 possible glycated sites could be 
detected. Even though the focus of the investigation is a small protein such as RNase A where 
the number of glycated sites is relatively low, with the help of LC–MS, 6 glycated peptides 
with 8 possible modification sites were found.  
 
Location glycation sites Sequence 
Identified 
by LC-
MS 
Identified 
by 
boronate 
affinity-
MALDI  
   
6 5 
 
   
8 9 
 
[  1- 10] K1 or K7 or R10 KETAAAKFER  + DD 
[ 11- 31] K31 QHMDSSTSAASSSNYCNQMMK +   
[ 32- 39] R33 or K37 or R39 SRNLTKDR   DD 
[ 34- 39] K37 or R39 NLTKDR +   
[ 38- 61] R39 or K41 or K61 DRCKPVNTFVHESLADVQAVCSQK +   
[ 40- 61] K41 or K61 CKPVNTFVHESLADVQAVCSQK + +  
[ 62- 85] K66 or R85  NVACKNGQTNCYQSYSTMSITDCR +   
[ 67- 91] R85 or K91 NGQTNCYQSYSTMSITDCRETGSSK  +  
[ 92-104] K98 or K104 YPNCAYKTTQANK  +  
[ 99-124] K104 TTQANKHIIVACEGNPYVPVHFDASV + +  
 
Table 12: Comparison of affinity chromatographic–off-line MALDI method with LC–MS in 
terms of identified glycated peptides of RNase A. DD refers to the double glycated peptides. 
 
 
4.2.3 Application of boronate affinity tips for selective enrichment of Amadori 
products from digest of HSA collected from sera of patients suffering from type 2 
diabetes mellitus and healthy volunteers  
Four healthy volunteers and four patients suffering from type 2 diabetes mellitus were 
chosen to test the method described above for the mapping of the level of glycation of HSA. 
Patients were selected on the basis of the level of HbA1c and fasting plasma glucose. Because 
boronate affinity chromatography has been recognized to bind constituents comprising cis–
diol, the method allows monitoring fructosyl lysine (FL, Amadori product) and its derivative 
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after loss of water (FL-18) (Figure 10). For healthy volunteers, besides some important 
clinical parameters, the fasting plasma glucose was always less than 6.1 mmol×L–1. These 
values were by far the highest in patients 1 and 2 (12.17 and 13.02 mmol×L–1, respectively). 
For patients 3 and 4, slightly lower values were obtained (8.53 and 7.50 mmol×L–1, 
respectively). 
Because HbA1c was used for monitoring long-term glycaemic control in patients with 
diabetes mellitus, this value is thought to indicate glycaemic state over the most recent 1–2 
months. For all of the investigated patients, HbA1c was considered to be rather high (10.30, 
11.50, 11.82, and 11.30% as measured for patients 1, 2, 3, and 4, respectively). 
These two series of data served for the estimation of the glycaemic state of patients. 
HSA reflects the amount of blood glucose more rapidly than HbA1c; moreover, accounting 
for its relatively short (17 days) biological half-life, the glycation level of HSA is relevant to 
the condition of blood glucose over 2 weeks preceding the test. 
Approximately 300 µg of the digest of HSA (HSA was collected from each patient and 
healthy volunteer) was enriched under optimized conditions using boronate affinity tips. Also 
considering the results reported earlier, the bound constituents were released from the tips by 
means of a 1.2 M sorbitol solution. The eluate was then desalted on C60(30) and 
preconcentrated. Peptides remaining after this procedure were measured by MALDI–
TOF/MS.  
 
 
 
Results reported in Table 13 show single and double glycated peptides with the corresponding 
possible glycation sites monitored in healthy volunteers and patients. Besides the privileged 
glycation sites of K12, K233, and K525 being present in each individual, many other glycated 
K and R residues described previously were recognized [67]. Regarding the numbers of 
glycated peptides and the possible identified glycated residues with the exception of patient 4 
(whose fasting plasma glucose was the lowest), the clinical parameters can be associated with 
the glycation pattern obtained from mass spectrometric data.  
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Single glycated peptides 
Location Possible glycation 
site H1 H2 H3 H4 P1 P2 P3 P4 
[  1- 12] K4 or R10 or K12 + + + +   + + 
[ 11- 20] K12 or K20     +    
[ 52- 73] K64 or K73      +    
[ 65- 81] K73 or R81     + +   
[137-144] K137 or R144    + + + + + + 
[191-199] K195 or R197 or K199 +    +    
[219-225] R222 or K225  +        
[219-233] R222 or K225 or K233      + +  
[226-240] K233 or K240 + + + + + + + + 
[263-274] K274   +   +   
[314-323] K317 or K323      + +   
[318-336] K323 or R336     +  + +  
[337-348] R337 or R348   +   +  + 
[373-389] K378 or K389   +  + +   
[390-410] K402 or R410       +   
[437-445] K439 or K444 or R445       +  
[525-534] K525 or K534  + + + + + + + + 
[535-541] K536 or K538 or K541       +  
[561-573] K564 or K573        +  
 
Double glycated peptides 
 
Location Possible glycation 
site H1 H2 H3 H4 P1 P2 P3 P4 
[  1- 10] K4 and R10   +    +  
[198-209] K199 or K205 or R209 +        
[277-286] K281 and K286   +   +  + 
[403-414] R410 or K413 or K414 +        
[440-445] K444 and R445       +  
[525-534] K525 and K534    + + + + + + 
 
Table 13: Single and double glycated peptides comprised by FL residues (Amadori peptides) 
detected in patients (P1–P4) and healthy volunteers (H1–H4). 
 
 
 
Table 14 below summarizes the explored glycated peptides with a mass shift of 
144.042. They can be either FL (Amadori product) after a loss of water or 
tetrahydropyrimidine bound directly to arginine residues. Both are able to bind to a boronate 
resin due to the presence of vicinal diol. Results also indicate that peptides appearing at m/z 
1077.519 and 1783.938 are worth considering. The latter site was observed in all of the 
investigated digests belonging to the patients but was utterly absent from samples taken from 
healthy individuals. This can be clearly seen in Figure 23 below. The presence of a 
modification at m/z 144.042 was further corroborated by the corresponding PSD spectrum, 
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where the presence of a neutral loss was detected at m/z 1639.896, showing that the location 
of the modification can be at either K414 or R428. Similarly, the peptide at m/z 1077.519 
could be detected in only three diabetic patients. This modification located at R81 is 
considered to be a tetrahydropyrimidine attached, as expected, to arginine.  
More patients and control individuals need to be involved to make a decision as to 
whether these 2 peptides with the possible modifications can serve as potential biomarkers in 
diabetes mellitus. The method elaborated and reported here seems to be a powerful tool for 
the investigation of non-enzymatic glycation. 
 
 
 
 
 
Location Possible glycation site H1 H2 H3 H4 P1 P2 P3 P4 
[ 65- 73] K73     + +   
[ 74- 81] R81      + + + 
[137-145] K137 or R144 or R145 +  +   +   
[187-195] K190 or K195  +        
[191-199] K195 or R197 or K199 +        
[210-218] K212 or R218          
[219-225] R222 or K225  +  +     + 
[373-389] K378 or K389       + + 
[414-428] K414 or R428      + + + + 
[437-444] K439 or K444      + +  
[501-521] K519 or R521       +   
[520-525] K524 or K525 +  + +  + +  
[525-538] K525 or K534 or K536 or K358     +    
[535-545] K536 or K538 or K541 or K545    +   +  
 
Table 14: Peptides modified with glucose after a loss of water and detected in patients (P1–
P4) and healthy volunteers (H1–H4). 
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Figure 23: Comparison of mass spectra of HSA digest taken from sera of diabetic patients 
(P1–P4) and healthy volunteers (H1–H4) after enrichment of glycated peptides in the range of 
1760–1800 Da. The presence of the peak appearing at m/z 1783.938 in patients suggests the 
possible distinctive role of this peptide as a biomarker. Each spectrum was monitored in 
reflectron mode and a sum of 1000 shots. The matrix applied was DHB. a.u., arbitrary units. 
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5. New results reported in the dissertation 
 
5.1 Determination of the binding capacity of C30 and C60(30) fullerene-silica 
with Leu-enkephalin  
After the activation and equilibration, C30-silica and C60(30) were incubated 
overnight with a solution of Leu-enkephalin at different concentrations. The peptide 
concentrations of the supernatants represent equilibrium values with the adsorbed Leu-
enkephalin. The adsorption isotherms can be depicted plotting the concentrations of 
supernatants (Cequ) against the adsorbed amount. Data points fit the theoretical adsorption 
model of Langmuir with an excellent linear regression when plotting Cequ against Cequ/mads. 
The binding capacity of C60(30) is 31.5 mg/g, which is confirmed by a previously published 
result [42]. In the case of C30-silica the value is 153.9 mg/g showing a five times higher 
binding capacity. 
 
 
5.2 Identification of solid phases (C18, C30, C60(10), C60(30), C60(100)) on 
the sequence coverage of tryptic digest of HSA and fibrinogen 
DHB, CHCA and THAP were tested to identify the best MALDI matrix for mass 
spectrometric measurement of unfractionated tryptic digest of non-glycated HSA. DHB has 
proven to be the optimal matrix because of good resolution and reliable measurements with 
regard to mass accuracy. From 69% to 71% of sequence coverage was obtained by increasing 
the mass tolerance from 50 ppm to 150 ppm. Due to the favourable properties of DHB this 
matrix was further used for the MALDI analysis of both unmodified and glycated protein 
digests. Twenty pmol HSA digest was fractionated on each stationary phase: C18, C30, 
C60(10), C60(30), C60(100). The C18- and C30-silicas provided better sequence coverages 
(approximately 80%) than the C60-silicas. In the case of fractionation of 20 pmol fibrinogen 
the C30 and C60(30) materials yielded nearly the same results for Aα- and Bβ-chains of 
fibrinogen, but there was a remarkable increment for c-chain (64.9%) on C60(30) that means 
the total sequence coverage reached the best result 62.15%. The hydrophobicity and the 
length of the peptide do play an important part since those peptides have better access to the 
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alkyl moieties and therefore generated interactions stronger than to the spherical C60 
molecules. Due to the highest percentage of the aromatic amino acids in the c-chain of 
fibrinogen the π-π interactions between the peptides and the fullerene play more important 
role than in the case of Aα- and Bβ-chains. 
 
 
5.3 Determination of glycated sites of HSA and fibrinogen with C30 and 
C60(30)-silica 
Digest of HSA glycated for 28 days were fractionated on C60(30) and C30 solid phase 
particles, the results were compared with unfractionated glycated HSA digest and boronate 
affinity. Sixty-nine possible glycated sites of HSA could be identified altogether, 10 of them 
have never been described in the literature before. Data provided from SPE experiments 
made it possible to recognise glycations that could not be detected from the unfractionated 
digest. 
In the case of fractionation of glycated fibrinogen digest, the result cannot be compared with 
other data in the literature, since it has not been reported before. In the sequence of Aα-chain 
72 modifications were found, using C30-silica 67, by means of C60(30) 63 glycated residues 
could be identified in SPE experiments. Of all the modified sites in Bβ-chain there were 59, 
with fractionations on C30-silica nearly the same number 53 sites, and on C60(30) 47 sites. 
Forty-one possible glycated sites were found for the c-chain of fibrinogen. Results achieved 
using C30-silica (33 sites) and C60(30) (34 sites) were similar to each other. For instance, in 
c-chain glycation on R8, R35, R123, R246 and R421 residues were only possible to be 
explored employing C60(30). The possible glycated sites of fibrinogen were described first 
by Böddi et. al [85]. 
In the SPE experiments of glycated proteins C30-silica is a competitive candidate with regard 
to C60(30) concerning both the number of glycated sites and the number of bound peptides. 
The selectivity of these materials differs; C30-silica adsorbs larger peptides, while C60(30) 
possesses excellent binding capacity towards hydrophilic, arginine-rich small peptides. The 
findings may lie in the basis of a feasible SPE-off-line-MALDI method to be used for the 
investigation of polar constituents of complex biological samples.  
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5.4 Optimization of different approaches of elutions in the case of boronate 
affinity tips  
Miniaturized boronate affinity chromatography was found to be the optimal method 
for the selective enrichment of non-ezimatically modified peptides. The proper binding 
condition is known (150 mM ammonium chloride/ammonia buffer, pH 8.2) but the 
appropriate circumstances of elution have never been optimized before. Data obtained from 
electrochemical measurements allowed us to find the optimal elution procedure of the bound 
glucose. It could be carried out employing either acidic conditions or a highly concentrated 
solution of sorbitol. Elution carried out using a sorbitol solution at a concentration of 1.2 M 
was found to be more efficient than elution with formic acid at pH 2.0, although the more 
acidic solution was used; the more efficient the acidic media for the elution was. The solution 
of formic acid allowed us to identify 27 single glycated peptides, as long as elution with 
sorbitol has given 41 single glycated peptides. 
 
 
5.5 Desalting of glycated peptides using different sorbents 
After the elution of glycated peptides with sorbitol prior to MALDI–TOF analysis, the 
eluate consequently needed to be desalted. This was implemented using three different types 
of sorbents: the commercially available ZipTip, C60(30) and a homemade C18 silica. The 
eluates after using a sorbitol solution at a concentration of 1.2 M, were evaluated on the basis 
of the identified single and double glycated peptides and the number of possible glycated sites 
on HSA glycated for 28 days. These can be plotted by means of Venn diagrams (Figures 19, 
20 and 21) for the best presentation of the results.  
Ammonium chloride/ammonia buffer has proven to be the best binding buffer for selective 
enrichment of glycated peptides by boronate affinity chromatography. As the Venn diagrams 
show, 41 single glycated peptides were adsorbed with ammonium chloride/ammonia buffer 
by C60(30), of these 13 were unique with 8 possible glycated sites. While using ZipTip, 42 
single glycated peptides can be found, 12 were unique with 4 unique glycation sites.  
The choice of buffer and the way of elution, as well as the most appropriate sorbent used for 
desalting the eluate, were evaluated by means of Venn diagrams. The result were discussed on 
the basis of for 28 days glycated HSA digest in terms of the numbers of single and double 
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glycated peptides as well as the number of recognized glycation sites located on these 
peptides. 
Regarding the numbers of single and double glycated peptides and the possible modified 
residues, C60(30) was considered as a promising sorbent with respect to its performance 
toward glycated constituents. Moreover, its efficacy is competitive with commercial that of 
ZipTip. The application of C18 did not meet the requirements concerning the number of 
glycated peptides bound during the desalting procedure. 
 
 
5.6 Application of the new method for the detection of glycated peptides 
achieved from digested human serum albumin, collected from patients 
suffering from types 2 diabetes – compared to healthy volunteers 
The applicability of the method was demonstrated for the digest of HSA isolated from 
healthy volunteers and diabetic patients. However, both the control and the diabetic groups 
included only four individuals, more glycated peptides, and consequently more glycated 
sites, were recognized for patients suffering from type 2 diabetes mellitus having been under 
insufficient diabetic control when being monitored FL (Amadori product). 
The privileged glycation sites of K12, K233, and K525 were present in each individual. 
Results also indicate that peptides appearing at m/z 1077.519 and 1783.938 are worth 
considering, although peptide at m/z 1077.519 could be detected in only three diabetic 
patients. This modification, which located at R81, is considered to be an attached 
tetrahydropyrimidine. 
When detecting FL after a loss of water (FL-18), a distinctive peptide appearing at m/z 1783.9 
was observed in each diabetic patient but was not detected in healthy control individuals. This 
peptide is located in the region of [414–428] of HSA and incorporates K414 and R428. This 
peptide and its glycated sites may serve as a potential biomarker for diabetes; however, 
further research is required to confirm this observation. 
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Figure A: The effect of the N2 laser light on the co-crystallized matrix and sample molecules 
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Figure B. Nomenclature of fragment ions observed in ISD [7] 
 
 
 
